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CELL WALL AND ERGOTHIONEINE BIOSYNTHESIS IN M. TB
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Tuberculosis (TB) is one of the world’s oldest contagious diseases caused by
Mycobacterium tuberculosis (M. tb). With the emergence and spread of drug-resistant M.
tb strains, there is an urgent need to discover novel drugs and drug targets specifically
against drug-resistant strains and dormant bacteria. This dissertation focuses on M. tb
enzymes essential for the M. tb cell wall and ergothioneine biosynthesis. The M. tb cell
wall acts as a protective barrier due to the presence of unique lipids and mycolic acids.
Among these lipids, trehalose-dimycolate and mycolylarabinogalactan play a major role in
constructing and maintaining the outer membrane (mycomembrane) of the cell wall. The
Ag85 Complex (Ag85A, Ag85B, Ag85C) catalyzes the biosynthesis of these lipids. A
previous student in our lab showed that tetrahydrolipstatin (THL), an FDA-approved lipase
inhibitor, covalently binds to the Ag85C forming an acyl-enzyme intermediate. Based on
this finding, a library of THL derivatives was synthesized and tested against Ag85C and
Ag85A. As a result, a clear structure-activity relationship was observed for these
derivatives. Thus, the structural and inhibitory information of this study can be utilized to
develop selective novel inhibitors that target Ag85 enzymes. The second protein of interest
is EgtD, an essential enzyme for ergothioneine biosynthesis in M. tb. Ergothioneine is a
low molecular weight histidine betaine found in all domains of life. Ergothioneine is critical
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for maintaining bioenergetic homeostasis and protect M. tb against alkylating agents,
oxidative stresses, and antitubercular drugs. Two strategies were implemented to discover
inhibitors for EgtD; screened a library of histidine/histamine derivatives to identify peptidelike inhibitors targeting the L-Histidine binding site and screened drug libraries to identify
drug-like inhibitors targeting the AdoMet binding site. This study presents inhibitory studies
and X-ray co-crystal structures of a library of peptide-like inhibitors and the first discovery
of indole-containing inhibitors and inhibitors against M. tb EgtD.
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Chapter 1
Introduction
1.1 Mycobacterium tuberculosis
Mycobacterium tuberculosis (M. tb), the causative agent of tuberculosis (TB), is a
pathogenic bacterium belonging to the family Mycobacteriacea. These pathogenic
bacteria spread through the air and transmitted from an infected person to another via
respiratory droplets containing bacteria

1-2

. These bacteria primarily affect the pulmonary

system, bones, central nervous system, and other organs 3.
Once M. tb enters inside a host body, it interferes with host T-cell recognition and
limits the host's first-line of defense 4. The bacterial cells enter to the lungs, and the
alveolar macrophages in the lungs are phagocytose the cells 5. Then the bacterial cells
infect the macrophages or persist in a latent state, forming granulomas 6. Only 5-15% of
total infections progress to active TB 7. Actively dividing M. tb bacteria replicate inside
macrophages, destroy the macrophage cells by M. tb induced cell death programs 8, and
spread throughout the respiratory system and other organs

9-10

. During this stage, the

infected person experiences a constellation of symptoms including fever, cough, chest
pain, weight loss, night sweats, dyspnoea, fatigue, etc. 11.
As mentioned earlier, M. tb can enter a dormant/non-replicating state, surviving
intracellularly 12. This latent form of TB is not contagious 13. Currently available treatments
targeting the biosynthesis pathways in actively dividing bacteria do not effectively kill these
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dormant bacteria. These dormant bacteria are encapsulated in granulomas that can
persist from months to decades and are resistant to the entry of anti-TB drugs and exhibit
strong bias in effectiveness of the current treatments towards actively dividing M. tb versus
dormant M. tb 14. Therefore, there is a critical need for new drugs that either overcome this
bias or a drug combination therapy that target both the dormant and dividing bacteria.

1.1.1 Evolution of Tuberculosis and Treatments
Tuberculosis (TB) is a highly contagious disease spread rapidly by an airborne
transmission of M. tb

15

. By performing modern sequencing technologies for various

strains, it has been shown that the genus Mycobacterium originated 150 million years ago
and M. tb, which belongs to this genus, has survived over 70,000 years causing high death
rate. In the eighteenth and nineteenth centuries, TB, the disease caused by M. tb, was an
epidemic in North America and Europe. At that time the only way to control the spread of
the disease was to isolate patients in Sanatoriums 16.
In 1882, Robert Koch’s hallmark discovery of isolating the TB bacillus and
tuberculin provided opportunities to develop skin tests of detecting M. tb infection

17-18

.

With his discovery of tuberculin, the BCG (Bacille Calmette-Guerin) vaccine was
developed as a TB control strategy 19. Because of his great scientific discoveries, he was
awarded the Nobel Prize in physiology/medicine in 1905 20. These findings were led to the
investigation of Streptomycin (1944), Isoniazid (1952), Pyrazinamide (1954), Ethambutol
(1961) and Rifampicin (1965)

21-24

. Streptomycin was the first drug used to treat TB

However, M. tb developed antibiotic resistance to this drug almost immediately

26

25

.

. Then

Isoniazid was used to treat TB effectively and used Isoniazid-Rifampicin combination to
minimize the development of drug resistance 27.
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Today’s treatments for drug sensitive TB requires a 2-month course of Isoniazid,
Rifampin, Ethambutol and Pyrazinamide and 6 months course of Isoniazid and Rifampin
28

. In the cases of multidrug-resistant (MDR-TB) and extensively drug-resistant TB (XDR-

TB), most of the current treatments having unsuccessful treatment outcomes. In brief,
MDR-TB resistant to more than one drug from first line drugs, XDR-TB resistant to all first
line drugs, and totally drug-resistant TB (TDR-TB) resistant to all available anti-TB drug
regimens

29-31

. Figure 1-1 shows the first line and second line drugs used in current TB

treatments.
Table 1.1:
First line and second line drugs in TB regimens, drug discovery year, drug targets and
their mode of actions against M. tb 29.
First-line and second-line drugs
Isoniazid (1952)

Mode of action
Mycolic acid biosynthesis
inhibition

by

targeting

Enoyl-ACP reductase

Pyrazinamide (1954)

Protein synthesis Inhibition
by

First line drugs

targeting

ribosomal

subunit 30S

Ethambutol (1961)

Arabinogalactan synthesis
inhibition

by

targeting

Arabinosyl transferase.

Rifampicin (1963)

4

DNA transcription inhibition
by

targeting

RNA

polymerase.

Streptomycin (1944)

Protein synthesis inhibition
by targeting 30S ribosome
unit

Para-amino salicylic acid Folate synthesis inhibition
by
targeting
(1944)
Dihydropteroate synthase

Cycloserine (1955)

Peptidoglycan
inhibition
by
Ligase
and
racemase

synthesis
targeting
D-alanine

Kanamycin (1957)

Protein synthesis inhibition
by targeting 30S ribosome
unit

Second line drugs
Ethionamide (1961)

Mycolic acid biosynthesis
inhibition
by
targeting
Enoyl-ACP reductase.

Capreomycin (1963)

Protein synthesis inhibition
by targeting interbridge B2a
between the 30S and 50S
ribosome units

Amikacin (1972)

Protein synthesis inhibition
by targeting 30S ribosome
unit

5

DNA supercoiling and
protein synthesis inhibition
by targeting DNA gyrase,
topoisomerase, and 50S
ribosome subunit.

Ofloxacin (1980)

Drug-sensitive TB is treatable with Rifampicin, Isoniazid, Ethambutol, and
Pyrazinamide

32

. Due to the increase of resistance strains for Rifampicin and Isoniazid,

there is an increased limitation of current treatments

33

. Furthermore, multidrug-resistant

TB and extensively drug-resistant TB are becoming increasingly difficult to treat with
existing regimens

34

. And there is not yet enough evidence for total drug-resistant TB

treatments 31.
The drugs used in current treatments remain the same over the past several
decades, making minor improvements to the existing therapy. Therefore, it is urgent to
move a new way forward in discovering new drug targets, medicines, and vaccines.

1.1.2 Side effects associated with current treatments
Due to the TB treatment received from 6 months to 2 years or longer, patients may
experience adverse effects linked to these drugs

28

. Patients treated with Isoniazid and

Rifampicin observed hypersensitivity reactions, hyperglycemia, vision changes, and signs
of neurotoxicity

35

. Patients treated with Ethambutol for an extended period observed

blurred vision, red-green color blindness, skin rashes, and fever during the therapy

36

.

Moreover, Ototoxicity and Nephrotoxicity are the primary side effects caused by prolonged
use of Streptomycin and Amikacin/Kanamycin 37-38.
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The long-term experience of these side effects from TB treatments and therapies
contributes to feeling loneliness, depression, which leads to suicidal feelings and attempts
39

. Therefore, short-duration treatment and new drugs are needed with minimum side

effects.

1.1.3 The global distribution of TB

Figure 1-1:
The global distribution of TB cases in 2019 (the figure adapted from the world
tuberculosis report 2020).

TB impacts one-third of the population worldwide each year 40. Based on the M. tb
infections reported, many case numbers are found in African and Asian countries 40. The
reasons may be due to poor primary healthcare and public health functions, lack of access
to treatments, and limited diagnostic facilities 41-43.

7

The 2018 global TB report estimated that there were 10 million active TB cases
globally, with most cases found in the African region and southeast Asian countries

44

.

Based on the statistics, TB has caused 1.5 million global deaths in 2018 44. In 2019, there
were 206,030 MDR-TB cases reported which is a 10% increment of MDR-TB compared
to 2018 44-45.

1.1.4 Covid19- TB interaction
With the SARS-COVID-19 widespread outbreak, evidence is accumulating for the
possibility of an interplay between COVID-19 and TB as HIV and TB coinfection in the
past. HIV was among the major risk factors of developing active TB. In HIV/TB co-infected
people, there is a 20-30 fold higher risk of developing active TB. Considering the possibility
of SARS-COVID-19 and M. tb–TB combination, a most recent study has shown similarities
in the transmission method of pathogens and dysregulation of immune responses in both
COVID-19 and TB. If these two co-infected, the outcome would be more severe than those
infected with either one of these infections. It is still under investigation whether the
Coronavirus responsible for COVID-19, could activate latent TB and thereby worsen
infection 46-48.
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1.2 Antigen 85 (Ag85) Enzymes Project Overview
1.2.1 M. tb cell envelope
M. tb is classified as an acid-fast Gram-negative bacteria 49. The M. tb cell wall is
a lipid-rich cell wall that serves as an impermeable protective barrier for the bacterial cell,
preventing most drugs' entry

50

. As these bacteria are surrounded with lipid-rich,

hydrophobic structural wax layer, Gram staining tests cannot be used for identification
purposes. Therefore, Ziehl-Neelsen acid-fast staining is used in the identification of M. tb.
In this staining technique, the use of carbol-fuschin with a long heating step, facilitates the
formation of strong complexes between the stain and mycolic acids and lipids in the M. tb
cell wall 51-53.

Figure 1-2:
Schematic diagram of M. tb cell envelope (The figure was adapted from Marrakchi
H. et al., Chemistry and biochemistry, 2014 and not shown to scale).
PG- peptidoglycan, AG- arabinogalactan, GL- glycolipids, TMM- trehalose
monomycolate, PL- phospholipid, TDM- trehalose dimycolate.

9

There are four principal layers of the M. tb cell envelope. They are the cytoplasmic
membrane, periplasmic region, mycomembrane and extracellular space

54

. The

cytoplasmic membrane has a thickness of 7 nM, and it is mainly composed of
glycerophospholipids (GPLs) and Phosphatidylinositol Mannosides (PIMs) 55. These PIMs
are only found in M. tb, and it is one of the major components of the cytoplasmic
membrane. Moreover, these PIMs are further mannosylated to produce lipomannan and
then glycosylated with arabinose to form mannosylated lipoarabinomannan (ManLAM).
This ManLAM extends to the periplasmic and mycomembrane regions. Other lipids such
as phosphatidylglycerol, cardiolipin, phosphatidylinositol, phosphatidylserine, and
phosphatidylethanolamine can be found in the cytosolic membrane as well 56-58.
The periplasmic region has a thickness of 20 nM, and it consists of peptidoglycans
(PGs) and arabinogalactans (AGs)

54-55

. The PGs float in the periplasmic membrane and

are composed of N-acetylglucosamine (NAG) and N- acetylmuramic acids (NAM). The
AGs consist of β(1-5) or β(1-6) O-linked galactose repeating units connected to
peptidoglycan

through

a

phosphoryl-N-acetylglucosaminosylrhamnosyl

covalent

attachment 59.
The mycomembrane is 8 nM in thickness and composed of mycolic acids, the
unique lipid component in the mycomembrane

60

. AGs are covalently attached to this

highly hydrophobic mycomembrane layer to form mycolyl arabinogalactan (mAG), and this
forms the inner leaflet of the mycomembrane. In the outer leaflet of the mycomembrane,
trehalose 6’- monomycolate (TMM), trehalose 6,6’-dimycolate (TDM- cord factor),
phosphatidylinositol mannosidase, sulfolipids, lipomann, and ManLAM can be found.
Furthermore, poly acetylated trehalose molecules and phosphatidylinositol mannosidase
are found in the inner side of the mycomembrane 54, 61-63.
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The extracellular region, the outside of the mycomembrane, is composed of large
polysaccharide. These molecules are loosely attached to the mycomembrane and
proteins 54, 64-65. Previous studies have shown correlation between the thickness of the cell
envelope and bacterial resistance to drugs

66

. MDR-TB and XDR-TB causing bacteria

have a dense peptidoglycan layer, making the cell envelope thicker than the typical M. tb
bacterial cell 67-68.
These cell wall structural components are essential elements for bacterial
virulence and are involved in the process of macrophage infection. Briefly, to promote
infection, PIMs and ManLAMs of M. tb bind to the mannose receptors of host
macrophages and allow the macrophages to engulf the bacterial cells and form
phagosomes. The bacterial lipids and glycolipids are involved in deploying host protective
immunological responses during this infectious process. Additionally, some of the lipids,
of the M. tb cell wall, particularly TDM, inhibit phagosome maturation into
phagolysosomes. At this stage, M. tb adopts the ability to replicate inside phagosomes 6971

.
During infection, some of the protein molecules secreted by M. tb into the

extracellular region play a key role in stimulating responses by the host immune system.
The secreted proteins of the Ag85 complex (Ag85A, Ag85B, and Ag85C) are the dominant
antigens produced by M. tb. These proteins also play a significant role in pathogenicity
and cell viability 72-74.
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1.2.2 Mycolic acids (MAs)
MAs are the major lipid component found in the M. tb cell wall, and the composition
is about 60% of the cell wall lipids. 54, 61, 75.

Figure 1-3:
The chemical structure of mycolic acid.

As shown in Figure 1-3, the mycolic acid structure contains two branches: the short
α-chain (side chain) and the long meromycolate chain (main chain)

76

. The length of the

shorter α-chain varies from 20 to 26 carbons, and the meromycolate chain length varies
from 42 to 62 carbons 77. This meromycolate chain can contain double bonds (one or two),
cyclopropanes, ketone groups, methyl groups, or methoxy groups 76.

12

Previous studies have suggested that there are more than 30 enzymes associated
with the biosynthesis of MAs

76, 78

. As shown in Figure 1-4, M. tb utilizes the fatty acid

synthase cycle to synthesize α-chain and the meromycolate chain 76. In brief, CarboxyacylCoA and Meroacyl-AMP are produced separately from Malonyl-CoA using fatty acid
synthase I (FASI) and fatty acid synthase II (FASII) pathways. The synthesized

Figure 1-4:
Mycolic acid biosynthesis pathway and the mycolyl transferase activity (The
figure was adapted from Shahinda S.R et al., Current Molecular Pharmacology,
2019).

Carboxyacyl-CoA and Meroacyl-AMP are condensed by Polyketide synthase (Pks13) and
then reduced by CmrA to form TMM. The synthesized TMM is transported to the cytoplasm
via the MmpL3 lipid transporter. The MA of TMM is then transferred to another TMM to
produce TDM or transferred to AG to produce mAG by the Ag85 Complex enzymes 76.
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1.2.3 α/β-hydrolase fold

Figure 1-5:
The structure of Geobacillus stearothermophilus carboxylesterase (PDB: 1TQH)2,
representing the α/β-hydrolase fold (The figure was adapted from Olalla L et al.,
Journal of microorganisms, 2015).
α-helices are colored in red, β-strands are colored in yellow, connecting loops are
colored in green, and the residues in the catalytic triad are colored in blue.

Antigen 85 complex enzymes belong to the α/β-hydrolase superfamily that
catalyzes a variety of hydrolytic reactions

79

. The well-known members of this family are

carboxylesterase, carboxypeptidase, acetylcholinesterase, and lipase

80

. As shown in

Figure 1-5, this protein fold has eight parallel β-strands connected by α-helices to form a
central β-sheet structure. Enzymes belonging to this family have a conserved catalytic
triad with a nucleophile (serine, cysteine, or aspartate), a basic residue (histidine), and an
acidic residue (aspartate or glutamate). The nucleophilic elbow, a conserved structural
feature in this fold, is created by a tight turn connecting a β-strand to a trailing α-helix and
harbors the nucleophilic residue 81-83. Conversely, these enzymes have a variety of protein
sequences and substrate binding sites 82, 84.
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1.2.4 The Ag85 mycolyl transferases
As explained earlier, Ag85 Complex enzymes are involved in the mycolyl
transferase reactions 79, 85. This complex consists of three enzymes called Ag85A, Ag85B,
and Ag85C encoded by the fbpA, fbpB, and fbpC genes

86

. These gene knockouts show

that the cell walls are deformed and defective due to the lack of MAs formation 86-87.
Ag85 secreted homologous proteins function as biological monomers and contain
signal sequences at the N-terminal of the proteins that facilitate protein transport from the
cytoplasm to the periplasm of the cells through the cell membrane 72, 88. Comparing these
three enzymes, Ag85B is secreted at the highest levels 72, 89. The Ag85 enzymes are found
in the culture filtrate as well. Since transport from the periplasm to the extracellular region
for these proteins lack characterization, it is expected that the Ag85 enzymes found in the
culture filtrate have simply leaked from the periplasm during cell division

90

. Enzymes of

the Ag85 Complex share the Serine-Histidine-Glutamate catalytic triad and catalyze the
mycolyl transfer from TMM to another 6' hydroxyl- TMM to form TDM or the 5' hydroxyl of
the AG to form mAG 74, 91-92. Besides the catalytic site, these enzymes have allosteric sites
to bind sugar substrates and alkyl chains of the MAs 93-94.
The Ag85B X-ray crystal structure in combination with trehalose (PDB: 1F0P)
reveals two sugar-bindings

94

. One binding site is closer to the active site, and the other

sugar-binding site is far away from the active site. This distal sugar-binding site is located
in the middle of α-helix 9 and the base of α-helix 5 94. The X-ray crystal structure of Ag85C
in complex with octylthioglucoside (PDB: 1VA5) further confirmed these allosteric
substrate binding sites as the octylthioglucoside sugar groups binding at the same
positions as Ag85B - Trehalose structure (PDB: 1F0P)

95

. Furthermore, the active site of

15

the Ag85C- octylthioglucoside structure (PDB: 1VA5) is divided into a sugar-binding site,
and mycolic acid binding site, and mycolic acid binding site, and these structural data
provide insights about TMM binding 95.
The Ag85C and diethyl phosphate structure (PDB: 1DQY) further strengthen our
understanding of the enzymatic mechanism and how the structural features of the enzyme
active site support acyl transfer. Specifically one ethyl group of the diethyl phosphate
points towards the sugar-binding site and the other ethyl group to a hydrophobic cleft

93

.

This complex structure also provides information about the stabilization of the tetrahedral
intermediate by the oxyanion hole during the enzymatic reaction

93

. Upon binding diethyl

phosphate, a conformational change has been observed in the α-helix 9 from the native
kinked conformation to a relaxed conformation

93

.

Moreover, in this conformational

change, the catalytic histidine is displaced from the active site 93.

1.2.5 Ag85 catalysis mechanism.
The catalysis by the enzyme of the Ag85C Complex proceeds via a ping-pong
reaction, including two half-reactions 93. In the first half of the reaction, the acyl donor TMM
binds to the protein
catalytic serine

93

93

. Acting as a catalytic base, Histidine abstracts a proton from the

. The deprotonated serine nucleophilically attacks the carbonyl carbon

of the mycolic acid ester linkage of TMM and forms a tetrahedral intermediate. During this
first half of the reaction in Ag85C, α-helix 9 adopts a relaxed conformation, and the
catalytic histidine adopts a sequestered position. Then the tetrahedral intermediate
collapses, and trehalose is released by forming an acyl-enzyme intermediate (Ag85- MA
intermediate)

93

. It is not yet clear if the α-helix 9 of Ag85A or Ag85B adopts the same

relaxed conformation as observed for Ag85C.
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During the second half of the catalysis reaction, a second TMM molecule or AG
molecule bind to the sugar-binding part of the active site. Upon this binding, α-helix 9 and
histidine restore their catalytic conformations to deprotonate the second substrates. Then
the deprotonated TMM or AG nucleophilically attacks on the carbonyl carbon of the acylenzyme intermediate to form a second tetrahedral intermediate that is stabilized by the
oxyanion hole. Finally, this tetrahedral intermediate collapses and liberates TDM or mAG
93

.

1.2.6 Ag85 proteins as drug targets
Previous studies have shown that Ag85C is important for the production of mAG
in the mycomembrane, suppress the host immune system as well as affect M. tb cell
viability

72, 96

. Therefore, these enzymes are great targets for anti-TB drug development

and vaccine development. Chapters 2 and 3 of this dissertation mainly focus on the
inhibitory activity of Tetrahydrolipstatin (THL) derivatives towards Ag85A and Ag85C. THL
is a commercially available lipase inhibitor that has been shown to form a covalent
complex with Ag85C. Chapter 4 provides the discovery of novel inhibitors on Ag85A and
Ag85C identified from high throughput screening of a library of structure-based small
molecules. In this project, the discovery of covalent inhibitors, lead molecules, proteinligand interactions, conformational changes upon ligand binding, and their inhibitory
studies will lead to the design and development of more potent inhibitors.
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1.3 Ergothionine D (EgtD) project overview

1.3.1 Ergothioneine (EGT) and its functions

Figure 1-6:
Thione and thiol form of EGT tautomerism

In 1909, Charles Tanret first discovered EGT biosynthesis from ergot fungus
(Claviceps purpurea)

97

. This is a low molecular weight compound found ubiquitously in

all domains of life. As shown in Figure 1-6, EGT is in a tautomeric equilibrium between
thiol and thione forms

98-99

. Even though all organisms require this molecule, the EGT

biosynthesis pathway was discovered in actinobacteria, cyanobacteria, methylobacteria,
and fungi (Table 2)

100

. Interestingly, a previous study (Seebeck et al., 2010) has found

that this EGT biosynthetic pathway exists in M. tb as well 101. The actual function/functions
of EGT in M. tb is still unknown, but several studies have suggested that EGT functions
as an antioxidant, possibly in an analogous role as glutathione (GSH) in eukaryotes.
As shown in Figure 1-7, EGT helps bacteria to maintain their reductive cell
environment from oxidative stressors and to maintain bioenergetic homeostasis. This
protects M. tb from various alkylating agents, xenobiotics, metal chelators, and anti-TB
drugs 102-104.
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Figure 1-7:
The chemical structure and the roles of EGT in M. tb (The figure adapted from
Cumming B. et al., Antioxidants ad redox signaling, 2017).

There are five enzymes associated with the M. tb EGT biosynthesis pathway

101

.

They are EgtD, EgtA, EgtB, EgtC and EgtE. EgtD and EgtB knockouts have shown that
these two enzymes are essential for EGT biosynthesis 105. It has also been demonstrated
that EGT knockouts are more susceptible to oxidative stressors, most first-line and
second-line anti-TB drugs such as Isoniazid, Rifampicin, Clofazimine, and Bedaquiline 98,
103, 106

. These two enzymes have been identified as two essential enzymes of M. tb during

the murine macrophage infection

100

. Therefore, these EgtD and EgtB can be used as
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novel and effective drug targets to identify therapies against M. tb. Additionally, inhibitors
for these enzymes can be used to enhance the efficacy of current therapeutics
synergistically.

Table 1.2:
Organisms that possess a functional EGT biosynthetic pathway 100-101, 103.

•

Aspergillus fumigatus

•

Aspergillus niger

•

Aureobasidium pullulans

•

Burkholderia pseudomallei

•

Chlorobium limicola

•

Claviceps purpurea

•

Lactobacillus casei

•

Methylobacterium aquaticum

•

Mycobacterium tuberculosis

•

Neurospora crassa

•

Schizosaccharomyces pombe

•

Streptomyces coelicolor

1.3.2 Methyltransferases
Methyltransferases catalyze the transfer of methyl groups from S-adenosyll-methionine (SAM) to methyl group acceptors (substrates), liberating Sadenosylhomocysteine (SAH) and methylated products 107. The generated SAH is
involved in product inhibition when accumulated at high levels in the cells. To
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overcome this product inhibition, bacteria utilize SAH nucleosidases (MTAN) or
SAH hydrolase to hydrolyze the accumulating SAH 108-109.

1.3.3 S-Adenosyl-L-methionine (SAM)
SAM is the second most highly used enzyme-substrate after adenosine
triphosphate (ATP)

110

. This is a ubiquitous molecule required in every organism as the

methyl donor for most methyl transfer reactions. As shown in Figure 1-8, the sulfonium
moiety of SAM results in a highly reactive methyl group 111-112. The primary roles of SAM
are biological components methylation, epigenetic regulations, and autoinducer
production by acting as a methyl donor and a substrate. Decarboxylated SAM is involved
in the polyamine’s biosynthesis pathway

113-115

. Besides that, radical SAM enzymes

involve protein post-translational modifications and catalyze a range of reactions, such as
C-C bond formation, C-H bond activation, etc. 116-119.

Figure 1-8:
Structure of the S-Adenosyl-L-methionine (SAM) molecule
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1.3.4 Monitor methyltransferases activity using fluorescence
polarization assay
There are many direct and indirect methods to monitor the activity of
methyltransferases. But these methods are less sensitive and inefficient in High
Throughput Screening (HTS) studies. Moreover, some of these assays need radioisotopic
labeling of the substrates 120-121. These old methods depend on multiple enzymes that are
coupled together to convert the produced SAH into chromophores or luminophores to
monitor the enzyme activity 122. These methods have very low sensitivity to detecting SAH.
These assays are challenging to monitor the enzymes that have slow enzyme activities
122

. To overcome these challenges, our lab discovered a universal assay that directly

detects SAH. As shown in Figure 1-9, this assay utilizes a catalytically inactive MTAN

Figure 1-9:
The basic principle of the developed FP assay (This figure was adapted from Banco,
M.T et al., Analytical chemistry, 2018) .
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D198N variant that allows binding of a fluorophore attached SAH molecule (AdoHcyTAMRA). This assay detects the fluorescence polarization, monitoring the displacement
of AdoHcy-TAMRA that is bound to the MTAN D198N variant. This is a feasible and
reliable assay for HTS with a low number of false positives. Moreover, this assay has more
sensitivity, cost-effectivity, and versatility than the existing assays. This assay detects not
only SAH but also 5’-methylthioadenosine (MTA), Adenine monophosphate (AMP), and
Adenine diphosphate (ADP) that make this a universal assay for methyltransferases 123.

1.3.5 Ergothionine D (EgtD)
EgtD belongs to the class 1 methyltransferase superfamily
distinct domains of the structure of EgtD
the SAM binding domain

125

125

124

. There are two

. They are the histidine binding domain and

. The SAM binding domain has a classic Rossmann fold

comprising six parallel β-strands to form a β-sheet 126. Histidine binds to a binding pocket
at the histidine binding domain 1. EgtD is the only enzyme that has been discovered to
convert an amino acid to its betaine without the involvement of other enzymes

127

. As

mentioned earlier, EgtB and EgtD enzymes are essential for the biosynthesis of EGT in
M. tb, and necessary to control the infection of macrophage cells in mice

100

. Therefore,

EgtD can be used as a novel drug target as it is directly involved in bacterial virulence and
infection mechanisms 103.
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1.3.6 EgtD as a drug target
This project is about discovering novel inhibitors that target histidine binding site
and SAM binding site. As mentioned earlier, a competitive FP assay was utilized to
perform the HTS of drug libraries to identify inhibitors. Chapter 5 and 6 show a library of
histidine derivatives tested against EgtD and the first discovery of a novel set of M. tb EgtD
inhibitors. The X-ray crystal structures of EgtD in combination with histidine derivatives
and the novel inhibitors were obtained from co-crystallization experiments. Based on the
structural information and protein-ligand interactions, the rationale is to identify lead
scaffolds to design more potent inhibitors and bi-substrate analogs towards M. tb EgtD.
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Chapter 2
Evolution of THL Derivatives for the Inhibition of M.
tb Ag85A and Ag85C Enzymes

2.1 Background
Tuberculosis (TB), a calamitous disease, was classified as an epidemic by
World Health Organization (WHO) in 1993

128

. Recent 2019 data estimate 10 million

people are infected, and 1.2 million people die of TB annually
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. TB is caused by

Mycobacterium tuberculosis (M. tb), which has the natural ability to defend against and
resist certain antibiotics

129

. The evolution of drug resistance in M. tb is attributed to

chromosomal mutations in addition to its intrinsic resistance mechanisms, including drug
target alteration, overexpression of drug targets, disruption of prodrug activation, and the
activation of efﬂux pumps 129-131.
The emergence of drug-resistant M. tb strains is a global health concern
and demands the exploration of new strategies to overcome this challenge. One reason
M. tb is a problematic pathogen due to its protective cell wall 132. Trehalose 6,6’- dimycolate
(TDM) and mycolylarabinogalactan (mAG) are two unique lipid components that enhance
the permeability-barrier properties of the outermost lipid membrane

133-134

. The high

percentage of lipids in the form of mycolic acids (MAs) is an exceptional feature of M. tb
outer cell wall given rise to the name mycomembrane 135.
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The enzymes of the Antigen 85 (Ag85) complex, three homologous
transferases (Ag85A, Ag85B, Ag85C) that share a 68-79% sequence identity,136 play a
key role in mycomembrane maintenance by catalyzing the acyl transfer of MAs to produce
TDM and mAG

137-138

. These Ag85 enzymes act independently utilizing a well-

characterized ping-pong mechanism 139.
Genetic evidence supports the hypothesis for different roles of Ag85A, Ag85B, and
Ag85C in M. tb despite sharing high sequence similarity and the same catalytic triad.
Knockouts of the genes encoding Ag85A and Ag85B have revealed that they are
responsible for MAs attachment to the M. tb cell wall 140. Another study found that Ag85B
knockouts grown in macrophage-like cell lines lack any growth defects, whereas Ag85A
knockouts have exhibited growth defects in macrophage-like cell lines 141.
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Figure 2-1:
Tetrahydrolipstatin structure.

Tetrahydrolipstatin (THL) is a derivative of the naturally occurring human lipase
inhibitor lipstatin that inhibits the absorption of fatty acids in the body (Figure 2-1) 142. THL
is more stable than lipstatin and is commercially available as Orlistat, an approved anti-
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obesity drug

143

. The strained four-membered ring of the β-lactone class has displayed a

promising inhibition activity against serine/cysteine hydrolases

144

. THL has been shown

to inhibit the activity of Ag85C, which affects bacterial growth, viability, and pathogenesis
138, 145-146

. THL inhibits both dormant and active forms of M. tb 147-149. Covalent inhibition of

Ag85C results from a nucleophilic attack on the carbonyl carbon of the β-lactone ring of

Figure 2-2:
Ag85C/THL (PDB: 5VNS) binding site.
Figure 2-2 shows the surface representation of Ag85C (gray colored) and the binding
of the α and β-side chains of THL moiety to the protein. Carbon, oxygen, and nitrogen
atoms are colored in green, red, and blue.
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THL via serine124, leading to an acyl−enzyme-type inhibitor−enzyme complex (Figure 22).150-151 More recently, THL has also been found to inhibit: Rv3802 phospholipase A and
polyketide synthase-13 thioesterase domain (Pks13-TE).146, 150 All of these enzymes are
α/β hydrolases that catalyze reactions on lipid substrates. Since THL inhibits a number of
targets, we sought to explore structural modifications that might change the activity profile
of THL and presumably modify the target selectivity.
This study aimed to evaluate the role of α-chain, β-chain, and amino ester group
(peptidyl arm) substituents on inhibitory activity against M. tb Ag85A and Ag85C. Dr.
Steven Sucheck’s lab (University of Toledo) synthesized a library of structurally diverse
THL analogs employing substituents to the α-chain and peptidyl arm positions (Figure 23).

Figure 2-3:
THL scaffold. Schematic representation of α-side chain, and the amino ester group
(peptidyl arm) of the THL scaffold used in lead optimization.

28

2.2 Methods
2.2.1

Molecular

cloning,

protein

expression,

and

protein

purification of Ag85A and Ag85C

The gene encodes for Ag85A that was codon-optimized for Escherichia coli (E.
coli) expression was cloned in pET32 plasmid containing N-terminal cleavable
polyhistidine tag. The Ag85A plasmid was transformed into chemically competent E. coli
cells suitable for T7 protein expression. Cell cultures were grown in a carbenicillincontaining LB medium at 37 °C. When the OD600 nm of the culture reached 0.6, the culture
was chilled to the induction temperature. The gene expression was then triggered by the
addition of 1 mM isopropyl β-D-1- thiogalactopyranoside (IPTG) at 16 °C. After 17 hours
of induction, cells were pelleted by centrifugation, and pelleted cells were resuspended in
20 mM Tris (pH 8.0) buffer. Following 30 minutes of incubation on ice with DNase and
Lysozyme, the cell suspension was lysed by sonication. The lysate was clarified by highspeed centrifugation, and the supernatant was loaded on to 5 mL cobalt affinity column
(Cytiva) pre-equilibrated with 20 mM Tris (pH 8.0) and 5 mM Imidazole. His-tagged
recombinant Ag85A protein was eluted with elution buffer containing 20 mM Tris (pH 8.0)
and 150 mM Imidazole. The targeted protein-containing fractions were pooled, and
Precision Protease (Cytiva) was added to remove the N-terminal His-tag. The protein
solution was incubated overnight at 4 °C against 20 mm Tris (pH 8.0), and His-tag cleaved
Ag85A protein was collected in the flow-through of immobilized cobalt affinity
chromatography. In the same manner, Ag85C was cloned, expressed, and purified from
E. coli.
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2.2.2 Ag85A and Ag85C activity assays
A previously published fluorescence-based assay was utilized to monitor the
enzymatic hydrolysis of 4-methylumbelliferyl heptanoate (4-MUH) (Sigma Aldrich) (Figure
2-4).152-153 The recombinant Ag85A and Ag85C proteins were purified as previously
described. Purified proteins were thoroughly dialyzed against 50 mM sodium phosphate
(pH 7.5) buffer, and all assays were performed in triplicate on a Synergy H4 Plate Reader
(Biotek) with λexcitation = 360 nm and λemission = 450 nm.

Figure 2-4:
Schematic representation of the 4-MUH assay

2.2.3 EC50 determination for THL derivatives
EC50 values were determined by generating dose-response curves via serial
dilution of THL derivatives. The reaction mixtures consisted of 100 nM Ag85A or Ag85C
enzyme and 4 mM trehalose in 50 mM sodium phosphate (pH 7.5) buffer. After adding the
respective THL derivatives concentrations or an equal DMSO volume, kinetic reads were
initiated by adding 50 μM 4-MUH immediately. The percent enzymatic activity was
calculated for each reaction according to the following equation after the subtraction of
background fluorescence.
% Enzymatic Activity = (V’/V’o)*100
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(V’ = inhibited rate, V’o = uninhibited rate of DMSO control)

The percent enzyme activity was plotted as a function of inhibitor concentration,
and data were fitted to the “[Inhibitor] vs. normalized response – Variable slope” within
GraphPad Prism 7.0. and EC50 values were determined by the equation given below.

y = 100 x 1/[1 + (EC50Hill slope/XHill slope)]

2.2.4 Crystallization and X-ray diffraction data collection
Recombinant M. tb Ag85C was concentrated to a final concentration of 200 μM,
and the co-crystallization experiment was performed by incubating protein-ligand mixture
at a 1:4 molar ratio on ice for 90 minutes. Crystallization experiments were performed
using the hanging drop vapor diffusion method using an equal volume of protein-ligand
mixture and reservoir solution. After incubation for 7 days at 16 °C, single crystals were
observed in a drop containing 8% v/v Tacsimate (pH 7.0) and 20 % w/v Polyethylene
glycol 3,350 (Hampton Research Index HR2-098). Crystals were mounted and flashcooled in liquid nitrogen following the addition of 10 % glycerol as the cryoprotectant. Xray diffraction data were collected at 100 K on beamline F at LS-CAT at the Advanced
Photon Source of Argonne National Lab.
The collected X-ray diffraction data were indexed, integrated, and scaled using
DIALS (Diffraction Integration for Advanced Light Sources) software.1 Following the
isomorphous replacement with previously solved M. tb Ag85C structure, the residues
within the dynamic loop (211-221) were removed, and the resulting model was subjected
to rigid body refinement and stimulated annealing in Phenix refine.4 The glycerol
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molecules and restraints were created using the eLBOW (electronic Ligand Building and
Optimization Workbench) and manually added to the model using coot.5-6 The model was
further refined with rounds of XYZ coordinate, real-space, occupancy, and B-factor
refinement in Phenix refine with manual model building in coot.

2.3 Results
2.3.1 Ag85A and Ag85C cloning and purifications

Figure 2-5:
Ag85C PCR product.
The expected size is 840 bp (base
pairs). Lane 1: DNA ladder, Lane 2:
Ag85C gene

Ag85A and Ag85C genes that were codon-optimized for E. coli were amplified and
incorporated into pET-32 plasmids separately (Figure 2-5). The recombinant plasmids
were confirmed for the desired genes by DNA sequencing. The codon optimization helped
increase the protein expression levels for both Ag85A and Ag85C, yielding ~35 mg protein
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from 4L culture. Figure 2-6 shows the chromatogram from the Ag85C first cobalt
chromatography and the SDS-PAGE gel of Ag85C protein. The expected mass for the
Ag85C protein is ~33 kDa.

1

2

35 kDa

25 kDa

Figure 2-6:
Chromatogram from the cobalt affinity chromatography of Ag85C and the 12% SDSPAGE gel before polyhistidine-tag removal. Lane 1: protein ladder, Lane 2: Ag85C.

2.3.2 Enzyme activity screening
The inhibition of THL derivatives was evaluated by screening Ag85A and Ag85C
enzymes by a fluorescence-based assay using 4-MUH. The assay is based on the
hydrolysis of 4-MUH by esterases into a highly fluorescent 4-methylumbelliferone that
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can be measured in a microplate fluorimeter.153 The Z’ value for this assay was determined
using 24 reactions of positive controls (with enzyme present) and 24 reactions of negative
controls (without the enzyme present) (Figure 2-7). The Z’ value is calculated as 0.75,
using the following equation.

Z' = 1-(3*stdev(a)+3*stdev(b))/(| AvgRate(a)-AvgRate(b) |)
(a = positive controls, b= negative controls)

Figure 2-7:
The Z’ determination for the 4-MUH assay

Figure 2-8 shows a library of THL derivatives substituted with different functional
groups at the α-side chain position. Figure 2-9 shows the peptidyl sidearm substitutions.
These THL derivatives were synthesized by Dr. Steven Sucheck’s group at the University
of Toledo.
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Figure 2-8:
α-side chain substituted THL derivatives library.

Figure 2-9:
Amino peptidyl arm substituted THL derivatives
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Figure 2-10:
EC50 values of THL derivatives against Ag85A.

36

Figure 2-11:
EC50 values of THL derivatives against Ag85C.
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As shown in Figure 2-10 and Figure 2-11, dose-response curves were generated
to investigate the concentration dependence of the above THL derivatives for inhibition of
M. tb Ag85A and Ag85C. Overall, these data show that THL derivatives shown in Figures
2-8 and 2-9 are comparatively less potent against Ag85C, with derivative 10d exhibiting
the best potency against Ag85A and Ag85C. As the α-side chain substituted THL
derivatives were less potent against Ag85A and Ag85C, another set of THL derivatives
containing peptidyl arm substituents, and less bulky α-side chains, were synthesized
(Figure 2-12) and tested against Ag85A and Ag85C.

Figure 2-12:
Library of THL derivatives with less bulky α-side chains and peptidyl arm substituents.
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These derivatives were tested against Ag85A and Ag85C and the generated doseresponse curves were shown in Figure 2-13 and 2-14 respectively.

Figure 2-13:
EC50 determination for the compounds shown in Figure 2-12 against Ag85A
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Figure 2-14:
EC50 values for the compounds shown in Figure 2-12 against Ag85C
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The compounds shown in Figures 2-8 and 2-9 possess varying steric bulk groups
substituted at the α-side chain. As mentioned earlier, those compounds exhibited
moderate potency against Ag85 enzymes.
Therefore, another set of THL derivatives was tested that synthesized by
introducing less bulky α-side chains (Figure 2-12). Depending on the obtained EC50
values, these compounds show maximum inhibitory activities against Ag85A and Ag85C,
with the highest inhibition observed from ADL-4-114 against Ag85A and ADL-5-32 against
Ag85C.
This new set of compounds seems more selective, facilitates the ligand access to
the active site, and stabilizes the binding. Besides that, the α-side chain substituents and
the thiol-reactive substituents at the peptidyl arm seem most prominent in elaborating the
protein-ligand complex's stabilization by selectively reacting with the cysteine209 nearby
the active site.
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2.3.3 X-ray crystallographic Structure Determination
The Ag85C crystals that formed in the presence of 10d diffracted to 2.5 Å resolution
(Table 2-1). Since all prior structures of Ag85C possessing a modified Ser124 residue, either
by chemical modification or mutation, exhibit a conformational change that relaxes the α9 helix, it was expected that 10d-modified Ag85C would also undergo this structural
change. However, to avoid bias with this assumption, the molecular replacement was
performed using the Ag85C native structure (PDB: 1DQZ) as the search model, and two

Figure 2-15:
Ag85C/10d crystals observed in 2% v/v TacsimateTM pH 8.0, 0.1 M Tris pH 8.5 and
16% w/v Polyethylene glycol 3,350. A single crystal was mounted and transferred to
a drop of 10% glycerol for cryopreservation. Crystal was flash cooled and stored in
liquid nitrogen to perform X-ray diffraction experiments at the Advanced Photon
Source facility at Argonne National Laboratory.
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molecular replacement solutions found in the asymmetric unit.2-3 Consistent with prior
structures and expectation, the difference density shows that α-9 helix is in the relaxed
conformation and the loop, residues 211-221, connecting this helix to the preceding ßstrand is disordered. This is consistent with covalent modification of the Ser124 nucleophile
reacting with 10d. However, difference density in the active site is not consistent with a
covalent modification of Ser124 during the X-ray diffraction experiment, so 10d was not built
into the final model.
Table 2-1:
Data collection and refinement statistics for Ag85C/THL10d structure.

Data Collection

Ag85C/THL10d

Wavelength

0.97872

Resolution range (Å)

59.46 - 2.51 (2.6 - 2.51)

Space group

P 1 21 1

Cell dimensions

a, b, c (Å)

59.46, 70.61, 68.59

α, β, γ (°)

90.00, 89.97, 90.00

Unique reflections

19458 (1920)

Completeness (%)

98.0 (94.3)

Mean I/sigma(I)

15.3 (8.4)
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R-merge

0.3565 (3.155)

R-meas

0.3971 (3.592)

CC1/2

0.822 (0.222)

Refinement

R-work / R-free

0.164/0.221

Number of non-hydrogen atoms

4371

macromolecules

4162

ligands

84

solvent

125

Protein residues

530

RMS(bonds) (Å)

0.008

RMS(angles) (°)

0.92

Ramachandran favored (%)

97.32

Ramachandran outliers (%)

0.00
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2.4 Discussion
2.4.1 α-side chain substituted THL derivatives inhibitory studies against
Ag85A and Ag85C (Figure 2-8 and 2-9)

As the inhibitory activity of 10d against both Ag85 targets is superior to the others
in the tested library, the X-ray crystal structure of a covalent complex with Ag85C and 10d
was pursued and compared to the Ag85C/THL crystal structure (PDB: 5VNS). While the
protein structure of Ag85C is well-resolved and the backbone structure is consistent with
that of the THL covalent complex, no difference density is observed for compound 10d
(Figure 2-16). This suggests that 10d reacts with Ag85C and the covalent complex is intact
during crystal formation, but the ester linkage is hydrolyzed prior to the X-ray diffraction
experiment. This hypothesis is further supported by the observation of both catalytic and
sequestered conformations of the catalytic general base, His260, which represent active
and inactive enzyme conformations, respectively (Figure 2-16). This suggests a water
molecule is activated by His260 in the catalytic conformation to promote ester hydrolysis of
the inhibitor-enzyme covalent complex. This contrasts with the stable Ag85C/THL covalent
complex where the N-formyl leucine moiety of THL prevents proper positioning of the
catalytic His260, water activation, and acyl-enzyme hydrolysis.154
Based on these results, the slightly more potent inhibition of the Ag85 enzymes by
10d in comparison to the other tested compounds may simply be due to a combination of
the less hindering α-side chain and the additional hydrophobic CBz moiety to promote
binding to the hydrophobic pocket affords nucleophilic attack on the ß-lactone. However,
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the apparently short-lived covalent complex with any of these compounds clearly limits the
relevance of Ag85 inhibition.

Figure 2-16:
The figure shows aligned X-ray crystal structures of Apo/Ag85C (orange colored,
PDB: 1DQZ)90, Ag85C/THL (gray colored, PDB: 5VNS), and Ag85C/10d (green
colored). As previously observed in the Ag85C/THL (PDB: 5VNS) structure, α9-helix
is in a relaxed conformation in the Ag85C/10d structure. The catalytic His260 adopts
both the sequestered and catalytic conformations as determined in the Ag85C/THL
(PDB: 5VNS) and Apo/Ag85C (PDB: 1DQZ) structures, respectively. The location of
His260 in the catalytic conformation may promote hydrolysis of the Ag85C/10d acylenzyme intermediate.
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Depending on the THL derivatives potency (EC50 values) represented in Figures
2-10, 2-11, and previous Ag85C/THL (PDB:5VNS) X-ray crystal structure, we envisioned
that the α-side chains of THL derivatives responsible for steering the ligand into the active
site and structural diversity of the α-side chains might hinder or position the ß-lactone in a
proper orientation to allow nucleophilic attack in shape specific manner. This hypothesis
is further strengthened by the observations from Figures 2-10 and 2-11. The observed
data show that α-side chain substituted THL derivatives are less effective against Ag85A
and Ag85C. Among these synthesized derivatives, 10d illustrates a relatively significant
influence on the potency of the Ag85A and Ag85C inhibitions. Compare to the other
derivatives, this derivative contains less hindering group substituted for the α-side chain.

2.4.2 Peptidyl arm substituted THL derivatives inhibitory studies against
Ag85A and Ag85C

Moving the hypothesis forward, we tested a new library of THL derivatives contain
less bulky α-side chains and thiol-reactive groups substituted to the peptidyl arm. As
shown in Figure 2-17, these groups expected to react with cys209 residue near the active
site to stabilize the covalent acyl-enzyme intermediate. And also, the less hindered α-side
chains of these THL derivatives will facilitate the initial binding and influence the structural
changes, as previously explained. The structural changes of the α-9 helix will help
cysteine to react with these thiol-reactive compounds. Strengthening this hypothesis, the
observed EC50 values of the inhibitors show strong evidence of excellent inhibition as
potent and specific inhibitors for Ag85C.
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Figure 2-17:
The figure shows the aligned X-ray crystal structures of Apo/Ag85C (orangecolored, PDB:1DQZ) and Ag85C/THL (gray-colored, PDB:5VNS) relative positions
of cysteine when the α-9 helix in the catalytic conformation and relaxed
conformation. As shown in this figure the peptidyl arm of THL (light blue color)
oriented towards the cys209. The flexibility of the dynamic loop formed upon the
ligand binding, will facilitate to undergo necessary structural changes in order to
bind thiol reactive groups to the target cys209.
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2.5 Conclusion
A series of THL derivatives were tested for inhibitory activities against Ag85A and
Ag85C enzymes to evaluate the influence of the α-side chain and the peptidyl arm
substituents on the protein-ligand binding specificity and the stability of the resulted
covalent acyl-enzyme complex.
Ag85A and Ag85C enzymes, two α/β hydrolases of M. tb involved in the
biosynthesis of mycomembrane, possess a hydrophobic cleft situated adjacent to the
catalytic site, which serves as a binding site for the α-chain moiety of THL. Binding of the
α-chain within the active site results in the positioning of the β-lactone moiety to facilitate
nucleophilic attack by the catalytic serine and results in the covalent modification of the
enzyme. THL derivatives containing less bulky α-side chains that are more effectively bind
to the Ag85 hydrophobic cleft, resulting in derivatives with increased specificity for M. tb.
The compounds are shown in Figures 2-8 and 2-9 are modest inhibitors of Ag85A
and Ag85C. Among these compounds, 10d showed the highest inhibitory effect on Ag85A
(34 ± 22 μM) and Ag85C (66 ± 8 μM). In this study, we also solved the Ag85C/10d crystal
structure that shows similar conformational changes with disrupted catalytic triad as
previously published Ag85C/THL structure. But the difference density of the bound 10d
ligand could not be found in the X-ray crystal structure. And the catalytic histidine can be
seen in the catalytic and sequestered form revealed that the formed acyl-enzyme
intermediate hydrolyzed.
The compounds in Figure 2-12 showed great inhibitions among all these THL and
THL derivatives being ADL-4-114 (9 ± 2 μM) is the best inhibitor for Ag85A and ADL-5-32
for Ag85C (3 ± 1 μM). The thiol-reactive groups at the peptidyl arm position may facilitate
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stabilization of the acyl-enzyme intermediate, preventing hydrolysis. Therefore, this set of
THL derivatives significantly stable than the previously published THL and other designed
THL derivatives.
Additionally, our structural and inhibitory data provide useful information to design
and improve covalent inhibitors, including enhanced affinity, selectivity, and the stability of
the resulting acyl-enzyme intermediate.
Therefore, we can conclude that the structural diversity of the α-chain is important
to the geometric requirement of the nucleophilic attack by the enzyme for the subsequent
covalent inhibition. And the peptidyl arm is influencing the stability of the acyl-enzyme
intermediate by preventing the reformation of sequestered histidine to limit water
activation. The introduction of thiol groups at the peptidyl arm seems like preserve the
acyl-enzyme complex. Using the THL as the lead compound, this study has discovered
the most potent and selective THL derivatives towards Ag85 enzymes. As THL is a known
inhibitor for other lipid esterases, we might use these THL derivatives as potent covalent
inhibitors for the other lipid esterases.
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Chapter 3

Second-generation Structure-based Drug Design
from Structural-inhibitory Studies of M. tb EgtDHistidine/Histamine Derivatives

3.1 Background
Ergothioneine (EGT) is a low molecular weight histidine derivative required by all
three domains of life

155

. Even though this ubiquitous molecule is found in all living

organisms, the biosynthesis pathway of EGT is found in actinobacteria, cyanobacteria,
methylobacteria, and fungi

97

. A recent study has been found the EGT biosynthesis in

Mycobacterium tuberculosis (M. tb)

156

. EGT plays a key role in maintaining bioenergetic

homeostasis in M. tb 157. Besides that, EGT defends M. tb against alkylating agents, heavy
metals, oxidative stressors, and anti-tuberculous drugs

157

. Because of these biologically

important characteristics of EGT in M. tb, the enzymes associated with its biosynthesis
pathway can be used as potent drug targets for tuberculosis (TB) treatments 97.
Due to the rising rate of drug-resistant TB and inadequate response to first-line
drugs, there is a need to investigate new drugs and drug targets

158

. The combination of

novel drugs identified in chapter 3 and chapter 4 with existing antibiotics would be a great
approach to improving current treatments' efficacy.
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Figure 3-1:
Biosynthetic pathway of EGT in M. tb. Multi-step pathway in which L-histidine is
converted into EGT in M. tb through a series of enzyme-catalyzed reactions.

As shown in Figure 3-1, the EGT biosynthesis pathway is occurring through five
enzyme-catalyzed steps

156

. The first step is catalyzed by Ergothionine D (EgtD), a

methyltransferase enzyme that catalyzes the trimethylation of L-histidine, leading to the
production of L-hercynine (N(α), N(α), N(α)-trimethyl-L-histidine)

155

. Ergothioneine B

(EgtB), a non-heme Fe-dependent enzyme, catalyzes the O2 coupled carbon-sulfur bond
formation between L-hercynine and γ-glutamyl cysteine and produces S-hercynyl-γglutamycysteine sulfoxide

159

. Ergothionine C (EgtC), a glutamine amidotransferase,

catalyzes the elimination of glutamate to form hercynyl cysteine sulfoxide 97. The final step
of this pathway is catalyzed by Ergothionine E (EgtE), a pyridoxal 5′-phosphate (PLP)
cofactor dependent enzyme that converts hercynyl cysteine sulfoxide to EGT 97.
By analyzing the genes encoding for these five enzymes, a previous study has
revealed that EgtB and EgtD are key enzymes in the biosynthesis of EGT

156

. Moreover,
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another study has found that the egtD gene, which encodes EgtD in M. tb, is essential for
EGT biosynthesis

160

. As illustrated in Figure 3-2, EgtD consists of a L-Histidine binding

domain and Adomet (S-Adenosyl methionine) binding domain that allows binding its

Figure 3-2:
X-ray crystal structure of M. smeg EgtD (PDB: 4uy6) 1.
L-Histidine binding domain is colored in red and Adomet binding domain (Rossmannfold domain) is colored in yellow. The figure shows the L-Histidine and SAH (SAdenosyl Homocysteine) binding in the adjacent binding sites. Previous studies have
suggested that SAH and SAM bind to the same binding site.
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substrates, L-Histidine and S-Adenosyl Methionine (SAM), respectively

161

.The

methyltransferase function of EgtD depends on the proximity of the methyl donor SAM to
methyl acceptor L-Histidine to produce trimethylated L-Histidine (L-Hercynine) 1.
In this study, substrates binding sites have been used as targeting strategies to
identify inhibitors that interact directly with the enzyme to inhibit the methyltransferase
activity. High-throughput screening of Histidine/Histamine derivatives library was
performed to discover novel inhibitors to this enzyme. This study provides the inhibitory
and structural information to diversify the scaffolds of lead compounds to design and
synthesis more selective inhibitors for the M. tb EgtD active site.

3.2 Experimental method
3.2.1 Molecular cloning, expression, and purification of M. tb EgtD
egtD gene that was codon-optimized to be expressed in E. coli was inserted into
pET 32 expression vector with carbenicillin resistance and cleavable N-terminal
polyhistidine tag. After confirming the DNA sequence, the engineered plasmid was
transformed into high-efficiency chemically competent T7 cells for protein expression.
Cells were cultured at 37 °C in carbenicillin-containing LB medium. Once the density of
the culture reached OD600

nm

= 0.6, the temperature of the shaking incubator was

decreased to 16 °C. When the culture was cooled down to 16 °C, 1 mM isopropyl β-D-1thiogalactopyranoside was added to induce protein production. After 24 hours of induction,
the cells were harvested by centrifugation at 4000 rpm, 4 °C. The cell pellets were
resuspended in lysis/wash buffer containing 50 mM HEPES (pH 7.5), 300 mM NaCl 10%
glycerol and 5 mM Imidazole. Then the cell suspension was treated with DNase I and
Lysozyme and incubated on ice for 30 minutes. Following the sonication, the cell lysate
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was centrifuged at 11900 rpm, 4 °C, for 40 minutes to pellet the cell debris. The clarified
supernatant was loaded onto a 5 mL cobalt affinity column (Cytiva) pre-equilibrated with
30 mL of wash buffer. Then washed the column with a 15-column volume of wash buffer
to remove unbound and non-specifically bound proteins. His-tagged protein was then
eluted using a gradient of 5-150 mM Imidazole containing wash buffer. Eluted protein was
then dialyzed against wash buffer after adding Precision Protease (Cytiva) to cleave the
affinity tag. The dialyzed proteins solution was applied to a 5 mL cobalt column preequilibrated with wash buffer and collected the polyhistidine tag cleaved protein in the
flowthrough. His-tagged removed protein was concentrated and employed for enzymatic
assays and crystallization experiments.

3.2.2 MTAN D198N purification
MTAN D198N protein purification was performed as previously mentioned

162

. In

brief, the codon optimized MTAN D198N gene was transformed into E. coli cells suitable
for T7 target protein expression. Transformed cells were cultured in carbenicillin contain
LB media at 37 °C until the OD600 nm reached 0.6. The culture was then cooled to 16 °C,
and 0.1 mM IPTG was added. After 12 hours of induction, cells were harvested by
centrifugation at 4000 rpm for 25 minutes. The pellet was resuspended in the lysis buffer
containing 100 mM HEPES (pH 7.5), 500 mM NaCl, 5 mM B-mercaptoethanol, and 5 mM
Imidazole. Following the addition of lysozyme and DNase I, the cell suspension was
incubated on ice for 30 minutes and sonicated. The sonicated cell lysate was centrifuged
at 11900 rpm for 45 minutes. The clarified supernatant was loaded on to 5 mL cobalt
column (Cytiva) pre-equilibrated with the lysis buffer. The unbounded and nonspecifically
bound proteins were washed with the lysis buffer, and the target protein was eluted using
a 5 mM-150 mM imidazole gradient. The eluted fractions were pooled, and Precision
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Protease (Cytiva) was added to cleave the polyhistidine tag. After dialyzing the protein
mixture overnight against the lysis buffer, the sample was applied to a second immobilized
cobalt affinity chromatography, and the purified target protein was collected in the
flowthrough. The concentration of MTAN D198N was measured utilizing the Bradford
assay and set to the working concentration for the FP assay.

3.2.3 AdoHcy-TAMRA purification
As previously published, 1.3 mg of S-adenosylhomocysteine (AdoHcy) was mixed
with 100 mM NaHCO3 (pH 9.0) and 1.0 mg of 5-carboxytetramethylrhodamine
succinimidyl ester (SE-TAMRA) in 100% DMSO 123. This reaction mixture was incubated
overnight at room temperature in a dark place to prevent photobleaching. The targeted
product was separated by Reversed-Phase High Performance Liquid Chromatography

Figure 3-3:
HPLC chromatography of the AdoHcy, SE-TAMRA reaction mixture after
overnight incubation. Red: absorbance at 545 nm, Black: absorbance at 260 nm.
The figure was adapted from Banco M.T., ACS Analytical Chemistry, 2017.
(RP-HPLC) based on the absorption spectra and retention times (tR) (Figure 3-3).
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3.2.4 Enzyme activity assay and EC50 determination for the
Histidine/Histamine derivatives
Previously published competitive fluorescence polarization (FP) based assay was
performed to monitor the displacement of fluorescently labeled AdoHcy (AdoHcy-TAMRA)
in complex with MTAN D198N

123

. In brief, the reaction mixture contains EgtD, MTAN

D198N, AdoHcy-TAMRA, Histidine, and a drug or an equal volume of DMSO. Upon the
addition of AdoMet, EgtD catalyzes the methyl transfer and form AdoHcy that binds to the
MTAN D198N, displacing the AdoHcy-TAMRA probe. All assays were performed in
triplicates using Synergy H4 Plate Reader (Biotek). Each drug was serially diluted and
added to the reaction mixture contains EgtD (11 nM), MTAN D198N (50 nM), AdoHcyTAMRA (11.3 nM), and L-Histidine (750 µM) to generate dose-response curves. AdoMet
(500 nM) was added to initiate the reaction and obtained the kinetic reads immediately.
After subtracting the background signal, the percent enzymatic activity (EC50) for each
reaction was calculated using the following equation where V’ represents the inhibited
rate, and V’o is the uninhibited rate of the DMSO control.

% Enzymatic activity = (V’/V’0) * 100

Then the % enzymatic activity was plotted as a function of inhibitor concentration.
The data were fitted to the “[Inhibitor] vs. normalized response – Variable slope” using
GraphPad Prism 7.0. EC50 values were determined using the following equation.

y = 100 x 1/[1 + (EC50Hill slope/xHill slope)]

58

3.2.5 Protein crystallization and X-ray diffraction experiments
The purified enzyme was concentrated to 200 µM and incubated on the ice at a
protein: inhibitor ratio of 1: 10. The hanging drop vapor diffusion method was used to set
up crystal screens by mixing equal volumes of protein-inhibitor sample and reservoir
solution. After overnight incubation at 16 °C, needle-shaped single crystals were obtained.
Crystals were cryoprotected (10% glycerol) and flash-cooled in liquid nitrogen for data
collection experiments. X-ray diffraction data were collected at 100 K on beamline D, LSCAT at the Advanced Photon Source (APS) in Argonne National Laboratory.

3.3 Results
3.3.1 EgtD purification

Figure 3-4:
EgtD affinity chromatography and SDS-PAGE gel. The figure shows the
chromatogram of the Immobilized cobalt affinity chromatography and 12% SDSPAGE gel of EgtD after his tag removal. The expected mass of EgtD is ~35 kDa.
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As shown in Figure 3-4, EgtD was purified using immobilized cobalt affinity
chromatography. In this purification technique, histidine tagged EgtD binds to the cobalt
column in higher affinity. This protein usually yields a higher protein expression level (~50
mg from 4L LB media culture). After histidine tag removal, a clean band was observed
from the 12% SDS-PAGE gel at ~35 kDa.

RFU

3.3.2 Z’ value determination

Time

Figure 3-5:
Z’ value determination for the FP assay. A set of positive controls and negative
controls were utilized to calculate the Z’ value. The obtained Z’ value for this assay is
0.75.

As mentioned earlier, a previously published FP assay was utilized to monitor the
activity of EgtD

123

. The Z' value was calculated using positive controls and negative

controls to determine the assay's sensitivity, accuracy, and reproducibility. The Z' value
was determined as 0.75, making the assay suitable for high throughput screening studies.
Utilizing this assay, a library of commercially available histidine and histamine derivatives
were tested to study the structure-activity relationship.
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3.3.3 Histidine/Histamine derivatives library
A library of commercially available histidine and histamine derivatives were tested
against M. tb EgtD to identify inhibitors that target the L-Histidine binding site. Based on
the previously solved EgtD crystal structures, there is a limited space to accommodate the
α-amino moiety of the bound L-Histidine. Therefore, different lengths of α-amino group
linkers were tested. Figure 3-6 shows the chemical structures of the ten purchased
compounds. EC50 values were determined to study the structure-activity relationship of
these compounds.

Figure 3-6:
Histidine/Histamine
derivatives
library.
Red
color
represents
histidine/histamine mimics and black color represents the different functional
groups tested.
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3.3.4 Dose-response analysis of Histidine/Histamine derivatives
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85 ± 12 µM

160 ± 60 µM

36 ± 4 µM

32 ± 4 µM

Figure 3-7:
EC50 curves for Histidine/Histamine derivatives. The figure represents the
generated dose-response curves using the EgtD coupled fluorescence
polarization assay. The EC50 values were calculated to the 95% confidence
range.

63

Figure 3-7 shows the best fit EC50 values of the generated dose-response curves
of Histidine/Histamine derivatives to 95% confidence interval. A wide micromolar range of
EC50 values was observed ranges from 21 µM to 240 µM. EgtD protein was co-crystallized
with Histidine/Histamine derivatives to investigate the protein-ligand interactions. The
obtained crystals were subjected to X-ray diffraction experiments. Section 3.3.5 of this
chapter summarizes the morphologies of observed protein-ligand co-crystals, X-ray data
collection statistics, structure refinement statistics, and protein-ligand interactions.
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3.3.5 EgtD-Histidine/Histamine derivatives crystal morphologies,
Data collection and refinement statistics, and protein-ligand
interactions

o EgtD-HD2

•

EgtD-HD2 crystal morphology

Figure 3-8:
EgtD-HD2 needle-shaped crystals. Needles like crystals were observed from
the hanging drop vapor diffusion method. Optimization of the crystal conditions
didn’t help to improve the diffraction quality of the crystal.
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EgtD protein was concentrated to a final concentration of 200 µM and incubated
with HD2 derivative on ice for 30 minutes at 1:10 protein to ligand molar ratio. The hanging
drop vapor diffusion method was utilized to initial screening of the crystal conditions using
a mixture of 1:1 (protein-ligand mixture to reservoir solution) drop ratio. After overnight
incubation at 16 °C needle-shaped crystals were obtained in the condition containing 0.2
M potassium sodium tartrate tetrahydrate, 20% w/v polyethylene glycol monomethyl ether
2,000 (Hampton Research-GRAS screen 2). Crystals were mounted directly from the drop
and cryoprotected by adding 10% glycerol and flash cooled in liquid nitrogen. The
observed co-crystals shown in Figure 3-8 were subjected to X-ray diffraction experiments
at the APS, Argonne national lab.
EgtD/HD2 crystal was diffracted to 2.7 Å resolution, and the diffracted data were
indexed, integrated, and scaled to P 21 21 21 space group using DIALS (Diffraction
Integration for Advanced Light Sources) software. The resulted model was subjected to
isomorphous replacement in Phenix refine using a previously solved M. tb EgtD structure
as the reference model. After another round of rigid-body refinement and stimulating
annealing, restraint for HD2 ligand was generated using eLBOW (electronic Ligand
Building and Optimization Workbench) and manually fitted to the difference density at the
histidine binding site using coot. The model was subjected to rounds of XYZ coordinate,
real-space, occupancy, and B-factor refinement in Phenix refine between manual building
in coot. The X-ray diffraction data collection and refinement statistics are presented in
table 3-1.
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Table 3-1:
X-ray data collection and refinement statistics for EgtD-HD2 crystal. Statistics for
the highest-resolution shell are shown in parentheses.

EgtD-HD2
Wavelength
Resolution range
Space group
Unit cell

0.97872
50.95 - 2.67 (2.765 - 2.67)
P 21 21 21
69.1022 71.5701 145.095 90 90 90

Unique reflections

21089 (2068)

Completeness (%)

99.84 (99.18)

Wilson B-factor
Reflections used in refinement
Reflections used for R-free

31.98
21067 (2059)
1995 (193)

R-work

0.2151 (0.2772)

R-free

0.2880 (0.3800)

Number of non-hydrogen atoms
macromolecules

5016
4974

ligands

30

solvent

12

Protein residues

642

RMS (bonds)

0.009

RMS (angles)

1.11
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Ramachandran favored (%)

97.18

Ramachandran allowed (%)

2.82

Ramachandran outliers (%)

0.00

Rotamer outliers (%)

0.00

Clash score

6.36

Average B-factor

30.02

macromolecules

30.04

ligands

29.11

solvent

26.04

Figure 3-9:
EgtD-HD2 structure. The figure shows the 2Fo-Fc maps (blue) for HD2 derivative
(carbon: green, nitrogen: blue, oxygen: red) contoured to 1.0 σ and the surrounding
histidine binding site residues (carbon: wheat, nitrogen: blue, oxygen: red).
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•

EgtD-HD2 interactions

Figure 3-10:
EgtD-HD2 interactions. The figure shows the interactions of HD2 derivative with
the histidine binding site residues of M. tb EgtD.

As shown in Figure 3-10, HD2 binds to EgtD, forming polar interactions with the
histidine binding site residues. In brief, HD2 forms a hydrogen bonding interaction between
the water molecule and the basic nitrogen atom in the imidazole moiety that acts as the
hydrogen bond acceptor. Besides that, the carboxylic group in the compound forms
hydrogen bonding interactions with Tyr206, Ser284 and Tyr56. This compound is
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commercially available as a mixture of L-HD2 enantiomer and D-HD2 enantiomer in a 1:1
ratio. The 2.7 Å resolution of the X-ray crystal structure of the EgtD-HD2 complex is not
sufficient to determine the stereochemistry of the ligand-bound.

o HD3

•

EgtD-HD3 crystal morphology

Figure 3-11:
Morphology of EgtD-HD3 crystals. The figure shows that the EgtD-HD3 needleshaped crystals. They were thicker and diffracted better than the EgtD-HD2
crystals.
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Figure 3-11 shows the EgtD-HD3 crystals obtained by co-crystallization. Tiny
needle-shaped crystals were observed after overnight incubation at 16 °C. Over time
these small crystals were transformed into a thick needle-like shape in 0.2 M potassium
phosphate dibasic, 20% w/v polyethylene glycol 3,350 conditions. Further crystal condition
optimization attempts didn’t help to enhance or change the morphology of the crystals.
One thicker single crystal was mounted and performed an X-ray diffraction experiment.
The crystal was diffracted to 2.5 Å, and the collected data were indexed, integrated, and
scaled to P 21 21 21 space group. The diffraction data and refinement statistics are
summarized in table 3-2.
Table 3-2:
X-ray diffraction data and refinement statistics for EgtD-HD3. Statistics for the
highest-resolution shell are shown in parentheses.

EgtD-HD3
Wavelength
Resolution range
Space group
Unit cell

0.97872
49.85 - 2.52 (2.61 - 2.52)
P 21 21 21
69.1463 70.2772 143.883 90 90 90

Unique reflections

24381 (2384)

Completeness (%)

99.86 (99.62)

Wilson B-factor
Reflections used in refinement
Reflections used for R-free
R-work

33.85
24352 (2375)
1993 (198)
0.2003 (0.2944)
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R-free

0.2691 (0.3563)

Number of non-hydrogen atoms

5115

macromolecules

4974

ligands

42

solvent

99

Protein residues

642

RMS (bonds)

0.010

RMS (angles)

1.54

Ramachandran favored (%)

96.87

Ramachandran allowed (%)

2.82

Ramachandran outliers (%)

0.31

Rotamer outliers (%)

0.20

Clash score

6.65

Average B-factor

35.66

macromolecules

35.53

ligands

51.24

solvent

35.19
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Figure 3-12:
EgtD-HD3 structure. The figure shows the 2Fo-Fc map (blue colored) for HD3
ligand (carbon: green, nitrogen: blue, oxygen: red) interpreted at 1.0 σ. The
surrounding residues are labeled (carbon: wheat, nitrogen: blue, oxygen: red). The
red color sphere represents the conserved water molecule at the histidine binding
site.

•

EgtD-HD3 interactions

Figure 3-13:
EgtD-HD3 interactions. The figure shows the interactions associated with HD3
ligand and the histidine binding site residues.
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As shown in Figure 3-13, the basic nitrogen atom in the HD3 imidazole moiety and
water interact to form a hydrogen bond. The carboxylate group interacts with Tyr56, Tyr206,
and Ser284 to form hydrogen bonding interactions similar to the EgtD-HD2 structure. Aside
from that, Tyr39 forms hydrogen bonding interactions with thiourea moiety and π-π
interaction with the aromatic phenyl ring of the HD3 ligand.

o HD6
•

EgtD-HD6 crystal morphology

Figure 3-14:
EgtD-HD6 crystals. Needle shape crystals were observed in the crystal condition
contain 0.2 M sodium sulfate decahydrate, 20% w/v polyethylene glycol 1,000. These
crystals were optimized by decreasing the polyethylene glycol concentration to
reduce the probability of nucleation. These optimization step helped to enhance the
quality of these protein crystals diffracting up to 1.8 Å. But it wasn’t reproducible for
the other EgtD-ligand complexes. The space group was determined as P 41 21 2.
The data collection statistics and the refinement statistics are shown in table 3-3.
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Table 3-3: Data collection and refinement statistics for EgtD-HD6. Statistics for the
highest-resolution shell are shown in parentheses.

EgtD-HD6
Wavelength
Resolution range
Space group
Unit cell

0.97872
49.35 - 1.72 (1.782 - 1.72)
P 41 21 2
69.7866 69.7866 144.469 90 90 90

Unique reflections

31266 (1383)

Completeness (%)

80.57 (36.20)

Wilson B-factor
Reflections used in refinement
Reflections used for R-free

21.55
31250 (1383)
2000 (89)

R-work

0.1866 (0.3379)

R-free

0.2293 (0.4466)

Number of non-hydrogen atoms
macromolecules

2834
2492

ligands

46

solvent

296

Protein residues

321

RMS (bonds)

0.014

RMS (angles)

0.97

Ramachandran favored (%)

98.75
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Ramachandran allowed (%)

1.25

Ramachandran outliers (%)

0.00

Rotamer outliers (%)

0.00

Clash score

3.98

Average B-factor

24.48

macromolecules

23.13

ligands

31.17

solvent

34.81

Figure 3-15:
EgtD-HD6 structure. The figure shows the 2Fo-Fc map (blue colored) for the HD6
ligand (carbon: green, nitrogen: blue, oxygen: red) contoured at 1.0 σ level. Position of
the residues with significant interactions to the HD6 ligand are labeled and colored as
carbon: wheat, nitrogen: blue, oxygen: red.
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•

EgtD-HD6 interactions

Figure 3-16:
EgtD-HD6 interactions. The figure shows the interactions between HD6
derivative and the histidine binding site residues.

Histidine moiety of the HD6 forms interactions in a similar way to that observed in
HD2 and HD3. Besides that, additional hydrogen bonding interactions can be seen
between the carbonyl group with Asn166 and water molecules.
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o HD7

•

EgtD-HD7 crystal morphology

Figure 3-17:
EgtD-HD7 crystals. The figure shows the obtained crystals for the EgtD-HD7
complex. These crystals have different morphological characteristics than the
previous protein-ligand complex crystals observed. These are comparatively thick
crystals that have straight edges. These were observed in the crystal condition
contain 0.2 M potassium sodium tartrate tetrahydrate, 20% w/v polyethylene glycol
monomethyl ether 2,000. This crystal morphology wasn’t reproducible with other
EgtD-ligands complexes. Even though this crystal possesses different morphology,
this was diffracted to 2.5 Å resolution like other crystal forms for this protein. The
space group was determined as P 21 21 21, and the X-ray diffraction data
collection, refinement statistics are listed in table 3-4.
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Table 3-4:
Data collection and refinement statistics for EgtD-HD7. Statistics for the highestresolution shell are shown in parentheses.

EgtD-HD7
Wavelength
Resolution range
Space group
Unit cell

0.97872
62.19 - 2.54 (2.631 - 2.54)
P 21 21 21
68.9172 70.8328 144.296 90 90 90

Unique reflections

23973 (2336)

Completeness (%)

99.87 (99.45)

Wilson B-factor
Reflections used in refinement
Reflections used for R-free

34.73
23952 (2331)
2001 (199)

R-work

0.2001 (0.2654)

R-free

0.2834 (0.3606)

Number of non-hydrogen atoms
macromolecules

5199
4974

ligands

72

solvent

153

Protein residues

642

RMS (bonds)

0.009

RMS (angles)

1.15
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Ramachandran favored (%)

94.98

Ramachandran allowed (%)

4.39

Ramachandran outliers (%)

0.63

Rotamer outliers (%)

0.00

Clash score

10.02

Average B-factor

35.47

macromolecules

35.34

ligands

43.04

solvent

36.29

Number of TLS groups

Figure 3-18:
EgtD-HD7 structure. As shown in this figure, the 2Fo-Fc map for the HD7 ligand
interpreted at 1.0 σ level. The ligand is colored as carbon: green, nitrogen: blue,
oxygen: red and the interacting residue is colored as carbon: wheat, nitrogen:
blue, oxygen: red.

1

80

•

EgtD-HD7 interactions

Figure 3-19:
EgtD-HD7 interactions. The HD7 ligand only forms one significant hydrogen
bond with Ser284. Other than that, this ligand might be stabilized based on the van
der waals interactions with the aromatic residues in the histidine binding site.
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3.4 Discussion
Previous studies have shown that the EgtD catalysis proceeds via processive
trimethylation of L-Histidine. Based on that study, L-Histidine bind first to the histidine
binding site, and then AdoMet binds to the AdoMet binding site to proceed with the
trimethylation of the L-Histidine molecule. It has been shown that there is no significant
structural change of the M. smeg EgtD (PDB 4UY6) protein upon the binding of LHistidine. The observed crystal structures of EgtD-histidine/histamine derivatives
complexes are shown in this chapter also do not show significant structural changes upon
the ligand bindings.

Figure 3-20:
EgtD structural change upon AdoHcy (SAH) binding. A: EgtD-His
complex molecular surface. B: EgtD-His-AdoHcy complex molecular
surface. This figure highlights the active site burial upon the binding of
AdoHcy molecule.

Conversely, the structures of AdoHcy and L-Histidine bound EgtD from M. smeg
(PDB:4UY6) shows the loop consisting of 85-90 amino acid residues undergo a structural
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change upon the AdoHcy binding. This structural change is shown to bury the L-Histidine
and AdoMet substrates to facilitate closer proximity for catalysis and substrate shielding
from hydrolytic reactions (Figure 3-20). The arrangement of hydrophilic and hydrophobic
residues throughout the active site would accommodate unique drug-target interactions.
Therefore, the hypothesis of this study was to design compounds that bridge histidine

Figure 3-21:
Identify a linker to bridge L-Histidine and AdoMet binding site. Based on
this figure, a library of histidine/histamine derivatives was tested as an approach
to identify a linker. As shown here, the active site is spacious enough to fit
histidine and SAH both simultaneously. Histidine and SAH are labeled and
colored as carbon: yellow, nitrogen: blue, and oxygen: red. The EgtD-His-SAH
complex (PDB: 4UY6) is represented as the molecular surface to highlight the
active site burial.
binding site and adomet binding site as shown in Figure 3-21.
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In order to evaluate this hypothesis, a library of commercially available histidine/histamine
derivatives were screened against EgtD in the presence of histidine and AdoMet, and the
resulted EC50 values with chemical structures are summarized in Figure 3-22.

Figure 3-22:
Chemical structures of Histidine/Histamine derivatives and corresponding
EC50 values. The histidine or histamine analogs are colored in red.
Based on the EC50 values, HD4 exhibited the highest inhibitory activity against M.
tb EgtD with the EC50 value of 25 ± 4 µM. The aromatic structure and the ether group may
interact with aromatic amino acid residues present in the histidine binding pocket.
Moreover, the less-bulky nature of the compound might facilitate the movement of the
ligand into the histidine binding pocket with minimal steric hindrance. HD5, HD10, HD2,
HD9, and HD3 derivatives show 30 µM - 47 µM inhibition activity against M. tb EgtD. The
existence of aromatic groups with carbonyl, ether, and thiourea groups may facilitate
interactions with the surrounding residues. The reduced inhibitory activity of HD8
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compared to HD1 could be due to the bulk nature of the ligand structure. These
histidine/histamine derivatives were co-crystallized with M. tb EgtD, and the crystals were
subjected to X-ray diffraction experiments to investigate protein-ligand interactions.

Figure 3-23:
The surface representation of the EgtD-HD2 complex. The figure shows the
clamshell-like structure of M. tb EgtD.

As shown in Figure 3-23, The clamshell-like structure of M. tb EgtD appears to
affect the X-ray diffraction experiments negatively. The histidine binding domain form one
half of the clamshell while the Adomet binding domain forms the other half of the clamshell,
and the active site is in the middle of the two halves of the clamshell arrangement. It is
believed that these two domains move relative to one another while remaining the two
domains in contact during the movements. Because of this unique structure and the
dynamic motions of these two mobile domains, weak/partial electron densities were
observed for the ligands bound in the active site.
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The aromatic amino acid residues in the histidine binding pocket might stabilize
the histidine/histamine derivatives in the histidine binding pocket. Therefore, the
histidine/histamine moieties of these derivatives buried in the histidine binding pocket have
comparatively high electron densities. The rest of these ligands extended to the AdoMet
binding site have relatively poor electron densities in the complex structures due to the
domain movements. Additionally, all these ligands are buried and lie in a similar
orientation.
As illustrated in Figure 3-21, there is a 4.4 Å distance-limited space between the
α-amino group of histidine and AdoHcy to fit a linker bridging these two substrates. The
EC50 values of , HD4, HD5, and HD10 derivatives showed the best inhibitory activity
against EgtD. The histidine or histamine moieties of these three ligands are coupled with
an amide linkage. Therefore, we can use the same approach by introducing an amide
coupling between the two substrates.
The HD2 inhibitor showed relatively the same inhibitory activity as HD10. But it
doesn’t include an amide linkage. Instead, it contains an α-carboxylate group. Therefore,
these observations suggest that the introduction of the α-carboxylate group promotes the
inhibitor binding.
The low inhibitory activities of HD9, HD3, HD7, HD6, HD1, and HD8 might be due
to the bulky groups attached at the linker region. As previously mentioned, the limited
space between the two substrates might be sterically hindered by the bulky groups of
these ligands yield the low inhibitory activities against EgtD. These inhibitory studies and
structural information can be utilized to design highly potent second-generation
histidine/histamine analogs to inhibit EgtD. Figure 3-24 shows a designed ligand targeting
histidine binding site as an EgtD inhibitor. Moving forward, Dr. Li’s group at The University
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of

Toledo

is

synthesizing

a

library

of

second-generation

structure-based

histidine/histamine derivatives using this inhibitory and structural information as a source.

Figure 3-24:
Lead identification and optimization. The figure shows the
use of experimental structural information of histidine
derivatives to improve the binding affinity by variation of
substituents.

3.5 Conclusion
Based on the inhibitory and structural studies of EgtD-Histidine/Histamine
complexes, ten target compounds were validated and identified that bind to the histidine
binding site. Using this inhibitory and structural information, we determined that employing
an amide linkage would be the best approach to link histidine and adomet binding sites.
This linker should be less sterically bulky attachments to accommodate the limited volume
between the histidine and adomet binding site. Besides that, this study is revealing the
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importance of the α-carboxylate group to the binding as well. This study provides structural
insights for the drug design strategies of second-generation histidine/histamine analogs,
bi-substrate analogs bridging the two-substrate binding site as potent inhibitors for EgtD.
The binding of these structure-guided novel ligands may stimulate significant structural
changes of the protein, leading to bury the active sites, which would be great inhibitors
with high binding affinities and specificities. These approaches may lead to more potent
inhibitors that simultaneously suppress the EGT production, xenobiotic tolerance
mechanisms, and M. tb bacterial virulence. Furthermore, these drugs would dysregulate
the bioenergetic homeostasis and enhance the anti-TB drug susceptibility. Therefore, in
combination with current medications, these drugs would lower the dose as well as the
duration of the current treatments.
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Chapter 4

Structural Insights into Novel Drug-like Inhibitors
of EgtD in Mycobacterium tuberculosis

4.1 Background
Ergothioneine (EGT) is a ubiquitous molecule found in all domains of life

163

. As

mentioned in chapter 1, the EGT biosynthesis pathway has been discovered in some
bacteria and fungi (Table 1-2) and appears to be highly conserved

105

. The presence of

specific human EGT transporter in higher animals is direct evidence of the ubiquity of this
molecule for the existence of life 164. As shown in Figure 1-6, EGT is a thione-thiol tautomer

L-Histidine

L-Hercynine

Figure 4-1:
EgtD catalysis reaction. EgtD catalyzes the trimethylation of L-Histidine to
produce L-Hercynine utilizing AdoMet (SAM) as the methyl donor. EgtD is the only
enzyme involving converting an amino acid into its betaine without coupling to other
enzymes.
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165

. The thione form is more stabilized and required by all living organisms and suggested

to involve in redox homeostasis 166.
EgtB and EgtD play an important role in the murine spleen and macrophage
infection process with M. tb

105

essential for EGT biosynthesis

. Furthermore, these two enzymes are shown to be

105

. Even though the specific functions of EGT have not

been known, previous studies have suggested that EGT plays an important regulatory role
in cellular activities by maintaining bioenergetic homeostasis and M. tb infectious
processes by enhancing bacterial virulence

103

. Moreover, it provides M. tb a defense

against oxidative stressors, alkylating agents, heat shock, UV irradiation, and anti-TB
drugs (Figure 1-7) 97.
As shown in Figure 4-1, EgtD utilizes SAM (AdoMet) as the methyl donor and LHistidine as the methyl accepter to produce L-Hercynine and SAH (AdoHcy) as the byproduct

124

. This EgtD catalysis is driven by the proximity and orientation of L-Histidine

and AdoMet in the two adjacent substrate binding sites. L-Histidine selectively binds to the
histidine binding pocket, and this binding site adopts the ability to distinguish the
stereochemistry of the D and L histidine

124, 167

. A recent study has found that the

subsequent methylation of histidine increases the binding affinity and specificity to the
histidine binding site 125.
There are numerous structural and inhibitory data available for EgtD in M. smeg.
But it is little known about EgtD in M. tb. There are no previously published structures and
no inhibitory studies published yet for M. tb EgtD. Since M. tb EgtD enzyme is a promising
drug target for TB, a previous student in our lab has screened two small-molecule libraries
comprising 715 compounds against M. tb EgtD. From this screening, we have discovered
the first set of novel inhibitors for M. tb EgtD. Another set of small molecule libraries was
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tested against EgtD in order to move forward in the drug discovery process. The
compounds identified as hits were co-crystallized with M. tb EgtD to determine the
structural characterization of the EgtD-ligand complexes.
Imatinib mesylate, a well-known tyrosine kinase inhibitor, is used to treat patients
with chronic myelogenous leukemia and tumors

168

. Interestingly, previous studies have

shown that this compound decreases M. tb and M. mamarium cell proliferation rate in mice
and macrophage cells. And it has also been suggested that imatinib inhibits the host
cellular entry of M. tb and the survival of the pathogen within macrophages 169-171.
There is a synergistic effect between rifampicin and imatinib towards M.
mamarium

169

. EgtD knockouts were reported to be more susceptible to rifampicin

103

.

Therefore, it is believed that EgtD is a biological target for imatinib. And this may be
affecting EGT biosynthesis as well.

Figure 4-2:
Imatinib chemical structure. This is a tyrosine kinase inhibitor
with a 2-phenylaminopyrimidine pharmacophore.
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4.2 Methods

4.2.1 Molecular cloning,
purification of EgtD

protein

expression,

and

protein

The experimental methods of EgtD cloning, expression, and purification are
mentioned in chapter 3, section 3.2.

4.2.2 Small molecule library screening
NIH clinical collection, Kinase Inhibitor libraries were screened at 100 μM utilizing
the EgtD coupled FP assay. As mentioned in section 3.2.4, the reaction mixture consists
of 10 nM EgtD, 50 nM MTAN D198N, 750 μM L-Histidine, 11.3 nM AdoHcy-TAMRA, 100
μM compound or equal volume of 100% DMSO (1% DMSO in the final reaction mixture)
in 50 mM TRIS (pH 8.0). The kinetic reads were initiated immediately after the addition of
500 nM AdoMet. The acquired data were converted to % Enzyme activities using the
equation below.

% Enzymatic Activity = (V’/V’o)*100
(V’ = inhibited rate, V’o = uninhibited rate of DMSO control)

The % Enzyme activity of each compound at 100 μM was plotted, and hits were
identified using 3𝛔 cutoff values. This was performed by obtaining the standard deviation
of the screening results and add three times of standard deviations to the calculated
average % enzyme activity of the screen. Compounds correspond to the data points below
3𝛔 cutoff were identifies as hits.
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4.2.3 Identified hits validation and EC50 determination
To validate the hits identified from the initial screen, dose-dependence curves were
generated, and the EC50 values were calculated. In brief, the reaction mixture contains 10
nM EgtD, 50 nM MTAN D198N, 750 μM L-Histidine, and 11.3 nM AdoHcy-TAMRA.
Serially diluted inhibitors or the equal volume of 100% DMSO was added to the reaction
mixtures while maintaining the DMSO at 1%. The kinetic reads were acquired immediately
after the addition of 500 nM AdoMet. Triplicate was done for each reaction condition, and
the % enzyme activity was calculated using the equation in section 4.2.2 after subtracting
the background. The calculated % enzyme activities were plotted as a function of inhibitor
concentrations, and the data were fitted to the “[Inhibitor] vs. normalized response –
Variable slope” utilizing GraphPad Prism 7.0 software. Finally, the EC50 values were
determined for the inhibitors using the equation below.

y = 100 x 1/[1 + (EC50Hill slope/xHill slope)]

4.2.4 EgtD co-crystallization with validated hits
The purified EgtD protein was concentrated up to 200 μM (Millipore EMD). The
concentrated protein sample was incubated with each inhibitor in a 1:10 molar ratio of
protein to inhibitor on ice for 30 minutes. Crystal conditions were set up using the hanging
drop vapor diffusion method. Each drop contains an equal volume of protein:ligand mixture
and reservoir solution. Index and several GRAS crystallizations screens (Hampton
Research) were tested for crystallization conditions for protein crystals using a mosquito
crystallization robot (TTP Labtech). After two days of incubation at 16 °C long rod-shaped
crystals were obtained. The obtained crystals were optimized by changing crystal
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condition parameters, and the morphologically best diffraction quality crystals with straight
edges were selected and cryoprotected (10% glycerol). The crystals were mounted and
stored in liquid nitrogen for X-ray diffraction experiments. The data sets for the EgtDinhibitor complexes were collected at the LS-CAT (Life Sciences Collaborative Access
Team) beamline at the APS (Advanced Photon Source), Argonne National Laboratory.
Data sets were indexed, integrated, and scaled using DIALS (Diffraction Integration for
Advanced Light Sources) and phased by isomorphous replacement with previously solved
EgtD-His crystal structure using Phenix refine. After a round of rigid-body refinement and
stimulated annealing, restrains for each inhibitor were created using eLBOW (electronic
Ligand Builder and Optimization) in Phenix and manually added them to the resulted
model using Coot.

4.3 Results and Discussion
In the previous chapter, a library of Histidine/Histamine derivatives was discovered
as inhibitors for M. tb EgtD. The X-ray crystal structures of those EgtD-Histidine/Histamine
complexes provided structural features and chemical information about protein-ligand
interactions as a basis for peptide-like inhibitors designing. The hypothesis of this study is
to discover drug-like inhibitors for M. tb EgtD as novel therapeutic agents. High-throughput
screening of commercially available drug/small molecules libraries technology was utilized
as an approach to identify promising inhibitors against M. tb EgtD.
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4.3.1 Discovery of indole-containing compounds as EgtD
inhibitors

Bisindolylmaleimide viii

EC50 = 1.4 ± 0.1 μM

Bisindolylmaleimide v

EC50 = 3.5 ± 0.6 μM
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Bisindolylmaleimide i

EC50 = 4.8 ± 0.3 μM

Naltrindole

EC50 = 9.0 ± 0.3 μM

From the High throughput screening of small molecule libraries, we identified a
unique set of indole-containing molecules that potently inhibit 50% of the EgtD enzyme
activity (EC50) below 10 μM. Among them, the best three inhibitors were found to be
bisindole

maleimide

compounds

showing

inhibitory

activities

below

5

μM

(Bisindolylmaleimide viii: EC50 = 1.4 ± 0.1 μM, Bisindolylmaleimide v: EC50 = 3.5 ± 0.6 μM,
and Bisindolylmaleimide i: EC50 = 4.8 ± 0.3 μM). Moreover, Naltrindole, an indole-
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containing compound, exhibited comparatively high potency with an EC50 of 9 μM ± 0.3
μM.
To further investigate the inhibitory mechanisms of these inhibitors, EgtD was cocrystallized, and the structures of the complexes were solved through X-ray
crystallography. The observed crystal morphologies and the crystal conditions are shown
in Figures 4-3, 4-4, and 4-5.

.

Figure 4-3:
EgtD- Bisindolylmaleimide v crystal morphology. These long rod-shaped
crystals were formed in a drop contains 0.2 M sodium acetate trihydrate and
20% polyethylene glycol 1000 (Hampton Research-GRAS screen 2). The
large rod-shaped crystal with the pointed end was subjected to an X-ray
diffraction experiment, and the crystal was diffracted up to 2.9 Å resolution.
The collected data were indexed, integrated, and scaled to the P 41 21 2
space group. The statistics for the data collection and refinement process are
shown in table 4-1.
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Figure 4-4:
EgtD-Bisindolylmaleimide i crystal morphology. Long rod-shaped
crystals with straight sharp borders were observed in the drop containing 0.2
M sodium acetate trihydrate and 20% polyethylene glycol 3350 (Hampton
Research-GRAS screen 2). The crystal was diffracted to 2.5 Å resolution,
and the collected data were processed to P 41 21 2 space group. The
refinement and data collection statistics are shown in table 4-2.

Figure 4-5:
EgtD-Naltrindole cubic-shaped crystal. A new form of co-crystal was
observed in the crystal condition containing 0.2 M DL - malic acid (pH 7.0),
20% w/v polyethylene glycol 1000 (Hampton Research-GRAS screen 2).
This crystal was diffracted to 2.8 Å resolution. The collected X-ray diffraction
data were indexed, integrated, and scaled to P 41 21 2 space group. Data
collection and refinement data statistics are represented in table 4-3.
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Table 4-1:
Data collection and refinement statistics for EgtD-Bisindolylmaleimide v complex.
Resolution range
Space group
Unit cell

49.58 - 2.942 (3.047 - 2.942)
P 41 21 2
69.269 69.269 141.979 90 90 90

Unique reflections

7845 (766)

Completeness (%)

99.58 (97.70)

Wilson B-factor
Reflections used in refinement
Reflections used for R-free

53.91
7837 (766)
784 (76)

R-work

0.2124 (0.2405)

R-free

0.2981 (0.3099)

Number of non-hydrogen atoms
macromolecules

2540
2487

ligands

46

solvent

7

Protein residues

321

RMS (bonds)

0.003

RMS (angles)

0.86

Ramachandran favored (%)

95.61

Ramachandran allowed (%)

4.08

Ramachandran outliers (%)

0.31
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Rotamer outliers (%)

0.78

Clash score

5.20
47.39

Average B-factor
macromolecules

47.33

ligands

50.79

solvent

46.28
1

Number of TLS groups
Statistics for the highest-resolution shell are shown in parentheses.

Table 4-2:
Data collection and refinement statistics for EgtD-Bisindolylmaleimide i complex
Resolution range
Space group
Unit cell
Total reflections

40.42 - 2.44 (2.527 - 2.44)
P 41 21 2
69.355 69.355 142.75 90 90 90
346821 (34576)

Unique reflections

13613 (1316)

Completeness (%)

99.54 (97.64)

Mean I/sigma(I)

6.06 (1.42)

Wilson B-factor

45.82

CC1/2

0.98 (0.982)

CC*

0.995 (0.995)

Reflections used in refinement

13557 (1285)
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Reflections used for R-free

1356 (128)

R-work

0.2037 (0.3582)

R-free

0.2642 (0.4217)

CC (work)

0.950 (0.702)

CC (free)

0.937 (0.604)

Number of non-hydrogen atoms
macromolecules

2573
2498

ligands

39

solvent

36

Protein residues

321

RMS (bonds)

0.008

RMS (angles)

0.97

Ramachandran favored (%)

95.92

Ramachandran allowed (%)

3.76

Ramachandran outliers (%)

0.31

Rotamer outliers (%)

2.33

Clash score

8.99

Average B-factor

52.53

macromolecules

52.22

ligands

74.40

solvent

50.11

Number of TLS groups

1
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Statistics for the highest-resolution shell are shown in parentheses.

Table 4-3:
X-ray data collection and refinement statistics for EgtD-Naltrindole crystal.

Resolution range
Space group
Unit cell

49.17 - 2.79 (2.89 - 2.79)
P 41 21 2
69.531 69.531 141.634 90 90 90

Unique reflections

9205 (907)

Completeness (%)

99.89 (99.89)

Wilson B-factor
Reflections used in refinement
Reflections used for R-free

60.60
9199 (906)
920 (91)

R-work

0.1691 (0.2030)

R-free

0.2465 (0.3019)

Number of non-hydrogen atoms
macromolecules
ligands
Protein residues

2529
2498
31
321

RMS (bonds)

0.008

RMS (angles)

1.33

Ramachandran favored (%)

97.18

Ramachandran allowed (%)

2.82
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Ramachandran outliers (%)

0.00

Clash score

5.98

Average B-factor
macromolecules
ligands
Number of TLS groups
Statistics for the highest-resolution shell are shown in parentheses.

62.92
61.95
141.20
1
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4.3.2

Interactions

between

EgtD

and

indole-containing

compounds
•

EgtD- Bisindolylmaleimide v interactions

A.

B.

Figure 4-6:
EgtD-Bisindolylmaleimide v interactions. A: The composite omit map of the ligand is
contoured to 1.0 σ level and depicted in a blue color mesh. B: polar and non-polar
interactions are showed in dashed lines.
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•

EgtD- Bisindolylmaleimide I interactions

A.

B.

Figure 4-7:
EgtD-Bisindolylmaleimide I interactions. A: The composite omit map for the ligand
is colored in blue and contoured at 1 σ. B: the polar interaction between ASN166 and the
ligand is represented in a black dashed line.
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As shown in Figures 4-6, and 4-7, the majority of the ligands were resolved in the
structures. The clamshell structure and the structural movements of EgtD domains cause
partial occupancies for the bound ligands. To investigate the protein-ligand interactions,
EgtD-Bisindolylmaleimide I, EgtD-Bisindolylmaleimide V, and previously solved EgtDBisindolylmaleimide VIII complexes were superimposed (Figure 4-8).

Figure 4-8:
The superimposition of EgtD-Bisindolylmaleimide structures. The EgtDBisindolylmaleimide I complex is colored in wheat (C: wheat, N: blue, O: red);
the EgtD-Bisindolylmaleimide V complex is colored in gray (C: gray, N: blue,
O: red); and the EgtD-Bisindolylmaleimide VIII complex is colored in green
(C: green, N: blue, O: red). The figure indicates the bisindolylmaleimide
ligands bind to the AdoMet binding site and L-Histidine, PEG and glycerol
bind to the histidine binding site of these complexes. The co-crystallization
experiments were performed for EgtD-Bisindolylmaleimide VIII complex in
the presence of L-Histidine and other complexes were co-crystallized in the
absence of L-Histidine.
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The superimposition of EgtD-Bisindolylmaleimide complexes allows us to evaluate
the SAR (Structure-activity relationships) of these selective bisindolylmaleimide
compounds against EgtD. The bisindolylmaleimide VIII compound shows the current
highest potency against EgtD exhibiting the EC50 value of 1.39 ± 0.04 μM. The highest
inhibitory activity of bisindolylmaleimide VIII compound might be due to the less stericbulky nature of the alkyl amine group compared to the other compounds. Because of less
hindered this compound may easily reach to the AdoMet binding site and afford a high
affinity binding than other compounds.
As shown in Figure 4-8, these Bisindolylmaleimide compounds specifically bind to
the AdoMet binding site. In addition, these compounds have bound less than 6 Å away
from the α-amino group of the L-Histidine. Therefore, we can design second-generation
indole-containing inhibitors with a peptide bound to an indole compound through a short
linker to bridge the histidine binding site and adomet binding site.
Furthermore, the histidine binding site accommodates PEG and glycerol
molecules in the absence of L-histidine. These molecules are mimicking the histidine
binding interactions, as shown in Figure 4-9. Therefore, we can utilize this information to
optimize/design inhibitors targeting histidine binding site as well.

Figure 4-9:
Glycerol and PEG molecules binding at the histidine binding site
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•

EgtD-Naltrindole interactions

A

B

Figure 4-10:
EgtD-Naltrindole structure. The figure represents the composite omit map (blue)
contoured at 1.0 σ and the surrounding residues available for interactions with the
ligand.
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EgtD-Naltrindole X-ray crystal structure reveals that naltrindole binds to the
adomet binding site of EgtD. This heterocyclic nitrogen-containing ligand may be stabilized
in the active site by the amino acids available for π-π, anion-π, and polar interactions
(Figure 4-10). Based on the observed 2Fo-Fc in composite omit map of the naltrindole,
this ligand exists as high conformational flexibility capable of interacting with the AdoMet
binding site. Therefore, the electron density is less well-defined to determine the individual
parts of the ligand.

• SU6668 inhibitor

EC50 = 8.1 ± 1.7 μM

Previous studies have shown that SU6668 (Oratinib) is a Tyrosine kinase inhibitor,
which is a chemotherapeutic drug that use to treat cancers

172-173

. This is an indole
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derivative that shows an EC50 value of 8.1 ± 1.7 μM against EgtD. To investigate proteinligand interactions, this compound was co-crystallized with EgtD, and X-ray diffraction
experiments were performed.

•

EgtD-SU6668 crystal morphology

Figure 4-11:
EgtD-SU6668 crystal morphology. A new form of crystal was observed for EgtD
in combination with SU6668. Crystal observed in a drop contained 0.2 M sodium
acetate trihydrate, 30% polyethylene glycol monomethyl ether (Hampton
Research-GRAS screen 2). This crystal was long rod-shaped thick crystals that has
a sharp end at the end. Straight edges were also observed. This crystal was
diffracted to 2.7 Å resolution and processed to P 41 21 2 space group. The data
collection and refinement statistics are shown in table 4-4.
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Table 4-4:
The X-ray diffraction data and refinement statistics table for EgtD-SU6668 generated from
phenix. The statistics for the highest-resolution shell are shown in parenthesis.

Resolution range
Space group
Unit cell

48.74 - 2.66 (2.755 - 2.66)
P 41 21 2
68.924 68.924 142.049 90 90 90

Unique reflections

9665 (943)

Completeness (%)

92.63 (92.18)

Wilson B-factor
Reflections used in refinement
Reflections used for R-free

52.20
9657 (943)
964 (94)

R-work

0.2061 (0.2386)

R-free

0.2714 (0.3164)

Number of non-hydrogen atoms
macromolecules

2535
2487

ligands

29

solvent

19

Protein residues

321

RMS (bonds)

0.009

RMS (angles)

1.13

Ramachandran favored (%)

94.98

Ramachandran allowed (%)

4.08
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Ramachandran outliers (%)

0.94

Rotamer outliers (%)

1.57

Clash score

10.45

Average B-factor

49.23

macromolecules

49.09

ligands

62.87

solvent

46.29
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•

EgtD-SU6668 interactions

Figure 4-12:
EgtD-SU6668 structure. The figure represents the 2Fo-Fc composite omit
map (blue) of SU6668 contoured to 1.0 σ and the interactions between
protein-ligand complex.
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As indicated in Figure 4-12, SU6668 forms polar interactions with Tyr206, Ser284,
and Gly161 backbone. The carboxylic group of the ligand mimics some of the interactions
of L-Histidine with the histidine-binding site, as illustrated in Figure 4-13. Interestingly, this
ligand extended to bridge the histidine binding site and the AdoMet binding site. This
compound shares structural similarities to the previous indole compounds because of the
presence of indolinone moiety. Therefore, it is strongly suggested that the AdoMet binding
site adopt more affinity towards indole compounds.

Figure 4-13:
M.smeg EgtD-Histidine (PDB:4uy6) structure. This figure shows the
polar interactions formed by L-Histidine with the histidine-binding site.
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4.3.3 Discovery of drug-like inhibitors of M. tb EgtD

• TGX-221 inhibitor

TGX221

%Enzyme Activity

100
80
60
40
20
0
0

20

40

60

80

100

Inhibitor (µΜ)

EC50 = 15.2 ± 0.8 μM

TGX-221 is a cell-permeable ATP-competitive inhibitor for P13K beta catalytic
subunits and other P13K isoforms. This drug is also used for cancer treatments

174

. As

shown in Figure 4-13, this binds to the AdoMet binding site. Since the similarities between
AdoMet and ATP suggest this compound competitively binds to the AdoMet binding site
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and extends to the histidine binding site. To evaluate the protein-ligand interactions, TGX221 was co-crystallized with EgtD. As shown in Figure 4-14, long rod-shaped large
crystals with straight and sharp borders were obtained. These crystals were
morphologically different than the other crystal forms observed for EgtD.

•

EGTD-TGX221 crystal morphology

Figure 4-14:
Thick rod shape of EgtD-TGX221 crystal. As shown in the figure, a cluster
of rod-shaped crystals were obtained from hanging drop vapor diffusion
method in the drop contained 0.2 M sodium acetate trihydrate, 30%
polyethylene glycol monomethyl ether (Hampton Research-GRAS screen 2).
The big rod-shaped crystals with straight edges were separated from the
other tiny needle shaped crystals and cryo protected with 10% glycerol. The
crystal was mounted and stored in liquid nitrogen for X-ray diffraction
experiments. This crystal was diffracted up to 2.2 Å resolution. The diffracted
data were indexed, integrated, and scaled to P 41 21 2 space group.
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Table 4-5:
Data table and the refinement statistics for EgtD-TGX221 complex. The statistics for the
higher resolution shell are shown in parenthesis.

Resolution range
Space group
Unit cell

49.31 - 2.201 (2.279 - 2.201)
P 41 21 2
69.019 69.019 140.922 90 90 90

Unique reflections

17958 (1712)

Completeness (%)

99.78 (98.33)

Wilson B-factor
Reflections used in refinement
Reflections used for R-free

38.47
17957 (1712)
1796 (172)

R-work

0.1799 (0.1740)

R-free

0.2293 (0.2338)

Number of non-hydrogen atoms
macromolecules

2595
2493

ligands

51

solvent

51

Protein residues

321

RMS (bonds)

0.007

RMS (angles)

0.88

Ramachandran favored (%)

97.81

Ramachandran allowed (%)

2.19
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Ramachandran outliers (%)

0.00

Clash score

2.98

Average B-factor

43.05

macromolecules

42.31

ligands

76.75

solvent

45.50

Number of TLS groups

1
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• EgtD-TGX221 interactions

Figure 4-15:
EgtD-TGX221 structure. This figure indicates the 2Fo-Fc omit map of the TGX-221
ligand contoured at 1σ and the ligand-protein interactions.
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The EgtD-TGX221 complex is stabilized in the active site by forming hydrogen
bonding interactions with Asn166 and Ser284 and the water molecule, as illustrated in Figure
4-15. Other than polar interactions, the heterocyclic rings of the ligand form π-π
interactions with Tyr39 as well. This ligand also acts as a bi-substrate analog binding to the
histidine binding site and the AdoMet binding site.

• (S)-Glycyl-H-1152 (hydrochloride) inhibitor

EC50 = 7.2 ± 0.5 μM
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(S)-Glycyl-H-1152 (hydrochloride) is a glycylated isoquinoline compound that is widely
known as ROCK (rho-kinase) inhibitor. This is also a membrane-permeable inhibitor that
selectively inhibits most other protein kinases as well 175.

Figure 4-16:
EgtD-(S)-Glycyl-H-1152 (hydrochloride) crystals morphology. Long rodshaped crystals with cubic shape end crystals were obtained in a drop
containing 0.2 M succinic acid (pH 7.0) and 20% polyethylene glycol 1000
(Hampton Research-GRAS screen 2). These crystals were diffracted to 2.4
Å and the collected data were indexed, integrated, and scaled to P 41 21 2
space group. The statistics for the data collection and refinement are shown
in table 4.6.
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Table 4-6:
The data collection and refinement statistics for EgtD-(S)-Glycyl-H-1152 (hydrochloride)
complex.

Wavelength
Resolution range
Space group
Unit cell
Total reflections
Unique reflections
Multiplicity
Completeness (%)

0.97872
39.11 - 2.39 (2.476 - 2.39)
P 41 21 2
69.281 69.281 142.127 90 90 90
214149 (6673)
12688 (759)
16.9 (8.8)
88.10 (53.91)

Mean I/sigma(I)

10.89 (1.18)

Wilson B-factor

50.82

R-merge

0.1502 (1.925)

R-meas

0.1547 (2.038)

R-pim

0.03619 (0.6386)

CC1/2

0.998 (0.634)

CC*

0.999 (0.881)

Reflections used in refinement
Reflections used for R-free

12659 (758)
1266 (76)

R-work

0.2020 (0.3704)

R-free

0.2851 (0.4335)

122

CC(work)

0.956 (0.783)

CC(free)

0.884 (0.715)

Number of non-hydrogen atoms
macromolecules

2528
2493

ligands

26

solvent

9

Protein residues

321

RMS (bonds)

0.008

RMS (angles)

1.00

Ramachandran favored (%)

97.18

Ramachandran allowed (%)

2.82

Ramachandran outliers (%)

0.00

Rotamer outliers (%)

0.00

Clash score

9.84

Average B-factor

57.94

macromolecules

57.73

ligands

78.54

solvent

56.73

Statistics for the highest-resolution shell are shown in parentheses.
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• EgtD-(S)-Glycyl-H-1152(hydrochloride) interactions
A

B

Figure 4-17: EgtD-(S)-Glycyl-H-1152(hydrochloride) interactions. A: The composite
omit map for the ligand
in green (C:
1 is contoured to 0.9 level. B: The ligand is colored
2
green, O: red, N: blue and S: yellow), and the histidine binding site residues
are colored
in wheat (C: wheat, O: red). The figure shows the binding of the (S)-Glycyl-H1152(hydrochloride) at the histidine binding site with interacting Tyr206 and Ser284. The
terminal amine moiety forms hydrogen bonding interactions with these4 two residues, and
the rest of the ligand is spanning along with the AdoMet binding site. The figure highlights
the interactions within 3.5 Å distance. The rest of the molecule is positioned in the AdoMet
binding site with weak Vanderwal and non-polar interactions.
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As a summary, these inhibitors exhibited the EC50 ranging from 1-15 µM.
Bisindolylmaleimide VIII compound displayed the greatest inhibition towards EgtD, with
an EC50 value of 1.4 ± 0.1 µM. The presence of electron-rich aromatic rings, indoles and
maleimide groups of these inhibitors may facilitate the ligand-protein interactions. To
investigate the protein-ligand interactions, EgtD was co-crystallized with these ligands. As
mentioned earlier, the clamshell structure and the structural movements of EgtD domains
cause partial densities for the bound ligands.
In the EgtD-Naltrindole complex, naltrindole binds to the adomet binding site.
Interestingly, SU6668, TGX-221 and (S)-Glycyl-H-1152(hydrochloride) ligands bind,
spanning both the histidine binding site and the AdoMet binding site. As shown in the
previous chapter, the structure alignment of the EgtD-AdoHcy-His structure and the EgtDHistidine structure from M. smegmatis shows a significant structural change upon
interaction with AdoHcy to afford a more closed conformation to shield the active site from
bulk solvent. Therefore, the significance of the AdoHcy binding leads to the structural
change that important to stabilize the overall movements of the structure. These novel
inhibitors are bound to a position that interrupts the movements of the loop, responsible
for the structural change of the enzyme. Therefore, the structural rearrangements do not
occur upon these ligands binding, and the EgtD structure remains in a clamshell structure.
This study reports the first discovery of EgtD inhibitors that target histidine binding
sites, AdoMet binding sites, and bi-substrate analogs targeting both substrate binding
sites. There is a structural similarity of the AdoMet binding site of all the
methyltransferases. Therefore, the inhibitors bind at the AdoMet binding site would not be
unique inhibitors to the targeting enzyme. But the histidine binding site residues are unique
for the L-Histidine binding, and the inhibitors targeting this unique inhibitor binding site
would be specific to EgtD. Moreover, the discovery of bi-substrate inhibitors, TGX 221,
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SU6668, and (S)-Glycyl-H-1152(hydrochloride), provide structural insights in designing
the next generation bi-substrate analogs that more specific and highly potent to EgtD that
stimulate the structural changes.

4.3.4 Imatinib mesylate (Imatinib) as a lead compound in the
development of EgtD inhibitors

EC50 = 8.8 ± 0.3 μM

In this study, we found another interesting tyrosine kinase inhibitor, Imatinib, that
shows a great inhibitory activity towards EgtD (EC50 = 8.8 ± 0.3 μM). This is a known
cancer drug that has been demonstrated synergistic activity in combination with rifampicin,
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a first-line drug, against M. tb

169

. As previously mentioned, that EGT is involved in

xenobiotic detoxification. Therefore, the combination of rifampicin and imatinib potentially
inhibit the EGT biosynthesis and thereby synergistically affect M. tb.
To evaluate the EgtD-Imatinib interactions, EgtD was co-crystallized in
combination with imatinib. The co-crystallization experiments were difficult to perform as
the protein is immediately precipitated by the addition of imatinib (1:10 ratio of protein to
ligand). After trying several crystallization experiments with different ratios of EgtD and
imatinib, I was finally able to obtain crystals of EgtD-Imatinib complex (1:2 protein to ligand

Figure 4-18:
EgtD-Imatinib complex crystals. Crystals were obtained in a drop containing
0.2 M sodium malonate pH 7.0 and 20% w/v polyethylene glycol monomethyl
ether 2000 (Hampton Research-GRAS screen 2). These crystals were
cryoprotected in 10% glycerol before the X-ray diffraction experiment. A single
crystal was diffracted up to 2.7 Å.
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ratio). These crystals were needle-shaped large single crystals with straight edges
compared to the other EgtD crystals.
A

pyridine-pyrimidine
rings of imatinib

B

Figure 4-19:
A: 2Fo-Fc map for the imatinib moiety at 1.3 σ. B: chemical structure of the imatinib
mesylate with piperazine moiety and the pyridine-pyrimidine moiety was
highlighted.
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As previously mentioned, imatinib is a tyrosine kinase inhibitor that competitively
binds to the ATP binding site. Because of the similarities between AdoMet and ATP, we
expected that imatinib would bind to the AdoMet binding site. Conversely, as shown in
Figure 4-19, we observed the pyridine-pyrimidine two rings bound at the histidine binding
site. The piperazine moiety of the imatinib molecule was also tried to fit into the density
observed at the L-Histidine binding site. But the steric hindrance arising from the protein
residues avoids the binding of imatinib in that orientation. The figure shows the electron
density map derived from the diffraction data for the histidine binding site that imatinib
bound. The two rings of imatinib that bind to the histidine binding pocket resolved well as
that part of the molecule are limited in movements by strong interactions in the histidine
binding pocket (Figure 4-19). But the rest of the molecule is extended to the ado met
binding site at the two-domain interface. The clamshell-like structure of the EgtD, as
shown in Figure 4-18, triggers the movements between two domains. Because of the
dynamic nature between these two domains and the flexibility of the ligand, the rest of the
imatinib molecule is disordered.
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Figure 4-20:
EgtD-Imatinib interactions. 2Fo-Fc map for the imatinib pyridine-pyrimidine
moiety at 1.3 σ and the significant interactions with the histidine binding site.
The pyridine-pyrimidine rings are colored in green (C: green, N: blue), and the
surrounding residues are colored in wheat (C: wheat, O: red).
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As shown in Figure 4-20, the pyridine-pyrimidine two rings of the imatinib molecule
are positioned in the histidine binding pocket by a hydrogen-bonding network. Because of
these strong interactions, this part of the molecule is well resolved.

Tyr39
Tyr206

Tyr56

3.6 Å

Asn166

Ser284

Figure 4-21:
Superimposition of M. tb EgtD-Imatinib (green) and EgtD-L-Histidine (gray)
structures. The figure shows the tetradentate interactions between the carboxylate
moiety of L-Histidine and Tyr56, Tyr206, Ser284, and Asn166 of EgtD. Tyr39 is positioned
as a potential hydrogen bond acceptor or donor.
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As shown in Figure 4-21, the pyridine ring of the imatinib structure overlapped with
the imidazole moiety of L-Histidine. The pyrimidine moiety is overlapped with the
carboxylate group of the L-Histidine. This structural information can be used to develop a
library of heterocyclic compounds as inhibitors for EgtD. Moreover, we can develop druglike inhibitors that mimic the tetradentate interactions, such as a sulfone group, with Tyr56,
Tyr206, Asn166, and Ser284 (Figure 4-21). As shown in the figure, Tyr39 located ~ 3.5 Å away
from the β carbon of the L-Histidine. Therefore, we can utilize this information to introduce
a hydrogen bond donor or hydrogen bond acceptor to form a hydrogen bond interaction
with the Tyr39.
Figure 4-22 shows a proposed lead molecule expected to bind to the histidine
binding site in high affinity and specificity using the two-ring system of imatinib.

Figure 4-22:
Proposed scaffold for the design and development of a library of heterocycles
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As illustrated in Figure 4-22, the introduction of the amine group to displace the
ordered water molecule may be or may not be affected to increase the binding affinity of
the ligand. If there is not enough space in the histidine binding pocket to displace the water
molecule, that would negatively affect to the ligand binding affinity. Therefore, it is
important to design inhibitors with and without this amine group to determine the effect on
the binding. Using the previous structures that bind to the AdoMet binding site, such as
bisindolylmaleimide compounds, we can expand this molecule in size to accommodate
the voluminous AdoMet binding site.

4.4 Conclusions
Chapter 3 is explained about the identification of peptide-like inhibitors that bind to
histidine binding site and linkers to expand the designed inhibitors from histidine binding
sites to the AdomMet binding site. Moving forward with drug discovery for EgtD, in this
chapter, we identified several drug-like inhibitors from small-molecule library screenings
that potently inhibit EgtD. Most of these compounds are currently used as FDA-approved
cancer drugs. Based on the observed inhibitory and structural data, we identified the
highest potent inhibitor that has yet been discovered against M. tb EgtD is
Bisindolylmaleimide VIII, with the EC50 value of 1.4 ± 0.1 μM. This study has found the
bisindolylmaleimide and indole-containing compounds are potent inhibitors for EgtD.
Furthermore, this study revealed imatinib as a lead compound to design a library
of heterocyclic compounds with high-affinity binding to the histidine binding site.
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Introduce
hydroxyl
groups

Introduce
indole group

Figure 4-23:
The superimposition of EgtD/TGX (green) and EgtD/SAH/His (yellow)
structures.
As shown in Figure 4-23, the structural information obtained from EgtD/TGX
structure can be utilized to design second generation drug like molecules that induce the
closed structural conformation as observed in EgtD/SAH/His structure. As shown in the
figure we can introduce hydroxyl groups and indole groups to induce the movement of the
loops in order to trap the compound in the active site in the closed form.
The discovery of TGX 221, SU6668, and (S)-Glycyl-H-1152(hydrochloride) are the
first identified bi-substrate inhibitors for M. tb EgtD. These protein-inhibitors interactions
and SAR studies give structural insight into designing more selective, unique secondgeneration drugs that would decrease the EGT production in M. tb and increase the
bacterial susceptibility, leading to shortening the duration of the current TB treatments.
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